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ABSTRACT
Melanoma is the most deadly skin malignancy and one of the most rapidly 
increasing cancers. Like other cancers, melanoma is known to exploit specific signaling 
pathways for growth and disease progression. The AKT pathway is aberrantly activated 
in upwards of 70% of melanomas and several lines of clinical evidence suggest that 
increased AKT signaling plays a role in melanomagenesis. However, in vivo 
experimental data directly testing the role of aberrant AKT activation in melanoma has 
been lacking.   
This dissertation addresses the role of aberrant AKT signaling in melanoma by 
expressing AKT isoforms and mutant protein in an established non-metastatic mouse 
model of melanoma. We report that expression of activated AKT1 in the context of 
BRAFV600E; INK4A/ARFNull melanomas result in highly metastatic disease with lung and 
brain metastasis. Interestingly, loss of Pten in this same context does not yield significant 
metastasis but in combination with activated AKT1 results in a significant increase in 
brain metastasis compared to AKT1 expressing melanomas with wild-type PTEN. 
Upregulation of mTOR pathway components is observed in AKT1 expressing 
melanomas compared to PTEN silenced counterparts. Expression of activated AKT3 in 
the context of BRAFV600E; INK4A/ARFNull melanomas results in significant 
metastatic disease to the brain while activated AKT2 expression in this same context does 
not result in observable brain lesions. Lastly, we investigated the role of AKT3E17K in 
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melanoma growth and metastasis. We report  no observable  brain metastases  and 
instead found  that  in vivo expression of AKT3E17K in  BRAFV600E;  INK4A/ARFNull 
melanomas yields highly aggressive lung lesions.  
In summary, this dissertation furthers our knowledge of melanoma by providing 
experimental evidence for the role of aberrant AKT signaling in melanoma metastasis to 
the lungs and brain. Mechanistically, our data reveal that PTEN silencing and AKT1 
activation differs in terms of promoting melanoma metastasis, that preferential organ-
specific metastasis appears to be mediated through specific AKT isoforms, and that the 
melanoma relevant mutant protein, AKT3E17K, may play a role in promoting lung 
metastasis. These findings advance our knowledge of melanoma and provide valuable 
insights for the clinical management of this disease. 
Hallelujah and thank you Jesus! 
Dedicated to my loving parents, Han Chun & Mi-young Cho 
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1.1 Melanoma Statistics 
Melanoma is a very aggressive cancer that accounts for less than 2% of all skin 
cancers yet causes the majority of skin cancer-related deaths (American Cancer Society, 
2015). It is one of the most rapidly increasing cancers in the United States with 73,870 
new cases of melanoma projected in 2015 (Siegel et al., 2015). The 5-year survival for 
localized (Stage I and II) melanoma is quite favorable at 98%, but the survival rates 
decline sharply to 63% and 16% for regional (Stage III) and distant metastatic (Stage IV) 
diseases, respectively (U.S. Cancer Statistics Working Group, 2014). These statistical 
data portray the gravity of melanoma and urgently call our attention to better understand 
the biology of this disease.  
1.2 Melanocyte Origin of Melanoma 
Melanoma is a cancer arising from melanin-producing cells known as 
melanocytes. During development, melanocytes emerge from highly migratory 
embryonic cells known as the neural crest and eventually occupy terminal niches such as 
the basal epidermis and hair follicles (Mayer, 1973). Melanocytes are not restricted to the 
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integumentary system and are known to also reside in anatomic locations such as the 
uvea, the inner ear, the heart, and the leptomeninges (Cichorek et al., 2013; Goldgeier et 
al., 1984; Plonka et al., 2009). The location of a melanocyte within the body appears to 
dictate its morphology, gene expression, and function (Whiteman et al., 2011). The 
migratory behavior of melanocyte precursors and the nonuniformity among melanocyte 
lineages correlate well with fundamental characteristics of melanoma such as metastatic 
propensity and disease heterogeneity.		
1.3	Melanoma Classification 
Melanoma is a heterogeneous disease comprised of several subtypes. Originally, 
the classification of melanomas into subtypes was based on gross clinical and 
pathological features (Arrington et al., 1977; Clark, 1967; McGovern, 1970). Four main 
subtypes were identified by the mid-1970s – superficial spreading melanoma, nodular 
melanoma, lentigo maligna melanoma, and acral lentiginous melanoma (Arrington et al., 
1977; Clark et al., 1969). Additional subtypes such as desmoplastic melanoma and 
nevoid melanoma were later added and currently at least ten melanoma subtypes are 
recognized by the World Health Organization (LeBoit et al., 2006). It was thought that 
each subtype of melanoma was associated with different prognoses and clinical 
behaviors; however, these notions were largely unfounded (Clark et al., 1969; 
Gershenwald et al., 2010; McGovern et al., 1979; Soong et al., 2010). Instead, clinical 
features such as tumor thickness, mitotic index, presence of ulceration, and other patient 
characteristics correlate with primary melanoma prognosis, regardless of subtype (Azzola 
et al., 2003; Francken et al., 2004; Scolyer et al., 2003). Moreover, melanoma subtyping 
based on World Health Organization criteria has not played a significant role in  
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determining clinical management (Scolyer and Prieto, 2011). The overall lack of utility 
significantly undermined the importance of melanoma classification until the 
recent acquisition of large genomic data sets and the emergence of targeted 
therapies based on genetic mutations made molecular classification clinically relevant 
(Bauer et al., 2011; Curtin et al., 2005; Hodis et al., 2012; Krauthammer et al., 2012). 
Although the current criteria for melanoma classification remains an ever-evolving 
concept, it is now universally recognized that melanoma encompasses several 
different types and should be addressed accordingly (Broekaert et al., 2010; 
Fecher et al., 2007; Scolyer and Prieto, 2011; Whiteman et al., 2011). 
1.4 Melanomagenesis 
During the mid-1980s, Clark and colleagues proposed a stepwise model of 
melanomagenesis beginning with benign melanocytes and ending with metastatic 
melanoma (Clark et al., 1984). They proposed that melanoma begins as a benign nevus 
(mole), an aggregated proliferation of melanocytes usually located at the 
epidermal-dermal junction or within the dermis. Clark et al. hypothesized that a benign 
nevus then progressively acquires characteristics such as cytological atypia and 
altered growth patterns eventually becoming a dysplatic nevus. From the pre-
cancerous stage of a dysplastic nevus, the model speculated that melanomas arise, 
initially as in situ lesions within the epidermal-dermal junction and subsequently 
transform into invasive melanomas. Upon breaching the dermis, it was then surmised 
that melanoma cells co-opt the circulatory and lymphatic systems to metastasize both 
regionally and to distant sites.  
The simplistic Clark et al. model, while full of limitations and exceptions,  
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provided a much-needed framework for thinking about the process of melanomagenesis. 
Two notable shortcomings were not addressed by this model: 70-80% of melanomas arise 
independent of a nevus precursor and 4-12% of melanomas have no identifiable primary 
lesion (Bevona et al., 2003; Gruber et al., 1989; Marks et al., 1990). However, in support 
of the Clark et al. model was the observation that 80% of human melanocytic nevi harbor 
an activating mutation in the v-Raf murine sarcoma viral oncogene homolog B (BRAF) 
gene, a mutation also observed in 40-60% of cutaneous melanomas (Hocker and Tsao, 
2007; Pollock et al., 2003; Poynter et al., 2006). In mice, melanocyte-specific expression 
of mutant BRAF promotes formation of benign nevi and only in combination 
with additional genetic modification gives rise to metastatic melanoma (Dankort et al., 
2009). These data support the theory of a step-wise transformation process whereby 
successive accumulation of genetic and/or epigenetic changes propel oncogenic 
transformation from melanocyte to melanoma (Miller and Mihm, 2006). 
1.5 Clinical Metastasis of Melanoma 
The aggressive nature of melanoma is defined by the disease’s propensity 
to metastasize, often early in the course of the disease. This is exemplified by the fact 
that while only 4% of all melanomas are diagnosed as stage IV, up to a third of all 
melanoma patients experience recurrent disease, mostly from unidentified metastases 
(Howlader et al., 2014; Soong et al., 1998). Melanoma metastasizes by a lymphatic, 
circulatory, or even para-vascular route (Bald et al., 2014; Zbytek et al., 2008). 
Clinically, the spread of melanoma manifests as one of the following: satellite/in-
transit metastasis, regional lymph node metastasis, and distant metastasis (Mervic, 
2012). The initial site of metastatic disease progression varies. About half of all 
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melanoma patients initially develop regional lymph node metastasis, a third initially 
develop distant metastasis, and the remainder present with satellite/in-transit skin 
metastases (Leiter et al., 2004; Meier et al., 2002). The presence of metastasis, like in 
other malignancies, poses an ominous sign for melanoma prognosis and is reflected by 
the successive decline in one-year survival rates for patients with one, two, or three 
different visceral metastases at 36%, 13%, and 1%, respectively (Balch et al., 2003). 
Thus, great vigilance is required in the clinical setting when monitoring melanoma 
metastasis and recurrence.  
Several prognostic tools have been developed over the years to better predict 
melanoma outcomes. The single most useful factor for prognosticating melanoma 
metastasis is primary tumor thickness, also known as Breslow thickness (Breslow, 1970). 
Follow-up studies clearly demonstrate that Breslow thickness strongly correlates with 
metastatic potential and recurrence (Schultz et al., 1990). Interestingly, even small 
differences in thickness (1-2 mm) can substantially alter prognosis (Balch et al., 2001). 
Regional lymph nodes are frequently the first noncontiguous site of metastasis in 
melanoma (Nathanson, 2003). A biopsy of the proximal most draining lymph node to the 
primary tumor, also known as the sentinel lymph node, is recommended for melanomas 
with Breslow thickness of 1 mm or greater, changing both treatment and prognosis based 
on the presence of absence of tumor cells (Balch et al., 2001). Other factors found to 
correlate with an increased probability of melanoma metastasis are ulceration of the 
primary tumor, presence of mitotic figures, and absence of tumor-infiltrating 
lymphocytes (Gimotty et al., 2004).  
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1.6 Biology of Melanoma Metastasis 
Melanoma-related deaths are universally due to complications from metastatic 
disease. This causal relationship holds true for the majority of cancers. An estimated 90% 
of all cancer-related deaths are attributed to metastasis and thus its study has elicited 
much attention (Mehlen and Puisieux, 2006). As early as the mid-1800s, the prominent 
physician-scientist, Rudolf Virchow, posited that sites of cancer metastasis were 
explainable by the circulatory migration of tumor cells (Virchow, 1989). This hypothesis 
seemed reasonable and in some malignancies, such as colon cancer, has found support 
(Hess et al., 2006). However, many tumors metastasize to specific organs in ways that 
cannot simply be explained by Virchow’s hypothesis. By the late-1800s, Fuchs and Paget 
countered Virchow’s hypothesis and proposed that tumor cells do not metastasize 
indiscriminately but instead have a predilection for colonizing specific organs  (Paget, 
1889; Piris and Mihm, 2007).  Thus was born the “seed-and-soil” hypothesis, where the 
“seed” or metastasizing cancer cell is thought to have a preference for growing in certain 
“soil” or organ niches. Paget’s initial finding from metastatic breast cancer patient 
autopsies strongly supported this alternative hypothesis and it continues to garner support 
to this day (Paget, 1889). 
The pattern of melanoma metastasis lends some support for Virchow’s hypothesis 
but is more often cited as strong evidence for the “seed and soil” theory.  Melanoma 
spreads regionally in a fashion that Virchow would have predicted. The most common 
sites of melanoma metastasis are adjacent skin and regionally draining lymph nodes 
(Balch et al., 2003). Metastasis to the nearby skin is one of the first external indicators 
that hematogenous and/or lymphatic spread has occurred (Wolf et al., 2004). In contrast, 
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the metastatic patterns of stage IV melanoma strongly support the “seed-and-soil” 
hypothesis with distant organs such as the lung, brain, liver, bone, and intestine as 
common sites of metastatic spread regardless of the primary lesion’s originating location 
(Patel et al., 1978). The lungs are often the first distant site melanoma colonizes while 
organs such as the intestines and bone usually represent areas of late metastasis (Balch et 
al., 2003). Brain and liver metastases exhibit an inverse correlation with the presence of 
one often excluding the other, implying a nonrandomness to melanoma dissemination. A 
subtype of melanoma involving the orbit known as uveal melanoma exclusively 
metastasizes to the liver in 55% of stage IV patients and involves the liver in 87-92% of 
all metastatic patients (Bakalian et al., 2008; Lorigan et al., 1991). Additional distant sites 
of melanoma metastasis are as follows: the heart, pancreas, adrenal glands, spleen, 
stomach, esophagus, thyroid gland, kidney, genitals, blood vessels, skeletal muscles, and 
other locations (Balch et al., 2003; Damsky et al., 2011b; Patel et al., 1978).  
Beyond clinical findings, melanoma cells provide experimental evidence that 
supports the “seed and soil” hypothesis. Hart and Fidler reported that B16 melanoma 
cells implanted into syngeneic mice preferentially grow in the lungs and ovaries but fail 
to grow in the kidneys (Hart and Fidler, 1980). They further demonstrated, through 
radiolabeling B16 cells, that initial tumor seeding in each organ was not significantly 
different, strongly supporting the idea of an organ-specific preference by the tumor cells. 
As mentioned earlier, uveal melanoma has a strong predilection for liver metastasis and 
laboratory findings support this preference. Following injection into nude mice, 
fluorescently-labeled uveal melanoma cells specifically colonize the liver and remain 
dormant in the liver for weeks (Logan et al., 2008). When human melanoma cell lines 
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derived from either cutaneous lesions, lymph nodes, or brain metastases were injected 
into the subarachnoid space of nude mice, all produced growths in the leptomeninges, the 
innermost layers of tissue covering the central nervous system (Fujimaki et al., 1996). 
However, only melanoma cells derived from the brain metastases were capable of 
invasion and growth within the brain parenchyma, suggesting these cells retained 
attributes that allowed site-specific growth. In line with this study, it was also 
demonstrated that human and mouse melanoma cells injected into the internal carotid 
artery of nude mice produce different patterns of cerebral metastases reminiscent of 
where the cells were derived from; cells from brain metastases colonized the brain 
parenchyma while cells originating from lymph node metastases took up residence in the 
meninges (Schackert et al., 1990). The clinical and experimental evidence for distinct 
patterns of distant melanoma spread has created much interest around the subject of why 
certain organs are targeted by melanoma. These answers are likely to be found deep 
within the genetics of melanoma.  
1.7 Genetics of Melanoma Metastasis 
 Among all cancer types, melanoma has the highest average somatic mutation 
burden (Alexandrov et al., 2013). The mutations harbored by melanoma are not entirely 
random and hold many clues about this disease. Our current understanding of melanoma 
biology stems largely from deciphering its genetic mutational landscape and identifying 
signaling pathways exploited by melanoma (Daniotti et al., 2004; Davies and Samuels, 
2010; Hodis et al., 2012). This section highlights a few of the important genetic 
alterations observed in melanoma and the functional relevance of these mutations in 
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melanoma metastasis. 
 The importance of Mitogen-activated protein kinases (MAPK) in 
melanomagenesis was first recognized through observations of Neuroblastoma RAS viral 
oncogene homolog (NRAS) mutations, which occur at a frequency of about 15%-20% of 
all melanomas (Albino et al., 1984; Albino et al., 1989; Padua et al., 1985). BRAF is a 
direct downstream effector of NRAS and BRAF mutations are found in ~50% of 
malignant melanomas (Davies et al., 2002; Pollock and Meltzer, 2002). Over 90% of the 
BRAF mutations in melanoma occur at codon 600, with the vast majority of these 
mutations rendering the substitution of glutamic acid for valine at the 600 amino acid 
position (Ascierto et al., 2012). Successful pharmaceutical interventions for metastatic 
melanomas harboring BRAF mutations further demonstrate the importance of MAPK 
signaling in this disease. 
 Aberrant activation of the Phosphoinositide 3-kinase/Protein kinase B 
(PI3K/AKT) pathway in melanoma is accomplished via several genetic alterations 
including deletions, inactivation, and epigenetic silencing of negative regulators and 
activating mutations and/or copy number amplification of positive regulators including 
the AKT isoforms. Phosphatase and tensin homolog,  also known as PTEN, is well 
known for its role in negatively regulating AKT pathway activity and 
deletions/inactivating mutations of this tumor-suppressor are observed in up to 43% of 
melanomas (Hodis et al., 2012; Mikhail et al., 2005). PH domain and leucine rich repeat 
protein phosphatase 1 (PHLPP1) selectively reduces AKT activation and its gene 
expression was recently shown to be suppressed in melanomas through a mechanism 
involving DNA methylation (Dong et al., 2014). Phosphatidylinositol-4,5-bisphosphate 
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3-kinase, catalytic subunit alpha (PIK3CA) is the kinase subunit of PI3K and activating
mutations in PIK3CA are observed in 1-5% of melanomas (Curtin et al., 2006; Omholt et 
al., 2006). AKT isoforms acquire activating mutations in 1-2% of melanomas (Davies et 
al., 2008), but more frequently genomic amplification or increased expression of AKT is 
observed in melanoma (Bastian et al., 1998; Stahl et al., 2004).  
 Disruption of the Cyclin dependent kinase inhibitor 2A (CDKN2A or INK4A/ARF) 
locus, which encodes two proteins, INK4a and ARF, is associated with familial 
melanomas and targeted in 55-70% of melanomas (Hodis et al., 2012). INK4a is a 
negative regulator of the retinoblastoma protein (pRB) pathway, which is critically 
involved in controlling the cell cycle (Sharpless and DePinho, 1999). The Alternate open 
reading frame (ARF) gene product regulates an equally important cellular pathway – the 
p53 pathway (Sharpless and DePinho, 1999). ARF is a negative regulator of Mouse 
double minute 2 (MDM2), the canonical negative regulator of p53, and functionally ARF 
acts as a positive regulator of p53 by promoting apoptosis in response to aberrant 
mitogenic stimuli. Thus, ARF mutations result in dysfunctional p53. Indeed, the 
importance of p53 loss is reiterated by the observance of mutations at this gene locus in 
about 20% of melanomas (Albino et al., 1994; Hodis et al., 2012).     
 Experimental evidence from transgenic mouse models confirm the importance of 
the genetic alterations observed clinically and also establish the existence of cooperation 
between mutations in promoting melanoma progression.  It had been noted that NRAS 
and BRAF mutations occur in a near mutually exclusive fashion (Colombino et al., 2012; 
Hodis et al., 2012). Activating mutations in BRAF frequently co-occur with PTEN 
mutations but are less frequently observed in NRAS mutant melanomas (Tsao et al., 
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2004). Since NRAS regulates both the MAPK pathway and the PI3K/AKT pathway, it is 
thought that combined activation of BRAF and PTEN silencing functionally mimics 
mutant NRAS and demonstrates that the two pathways cooperate in melanoma 
development. Interestingly, mice harboring a BrafV600E mutation in their melanocytes do 
not develop melanomas but in combination with Pten loss, their melanocytes transform 
into metastatic melanomas that spread to the lymph nodes and lung (Dankort et al., 
2009). Mice with global deletion of Ink4a/Arf develop a wide spectrum of tumors, but 
melanomas are not observed (Serrano et al., 1996). However, when deletion of Ink4a/Arf 
occurs in melanocytes in conjunction with MAPK pathway activity (via NRAS or HRAS 
activation), non-metastatic melanomas arise (Chin et al., 1997; VanBrocklin et al., 2010). 
Increasing the metastatic potential of melanomas in genetically engineered mouse models 
has been accomplished by further manipulating other cellular pathways via mutations to 
genes such as β-catenin and Liver kinase B1 (Lkb1) (Damsky et al., 2015; Damsky et al., 
2011a; Liu et al., 2012). These examples demonstrate how melanoma co-opts various 
cellular pathways to promote disease progression and lend a platform to further study 
organ-specific metastasis. 
1.8 Melanoma Brain Metastasis 
Brain metastases are a major complication of metastatic melanoma and are 
responsible for up to half of all melanoma deaths (Budman et al., 1978; Davies et al., 
2011; Yashin et al., 2013). Among all cancers that metastasize to the brain, melanoma 
has one of the highest propensity for colonizing this organ (Marchetti et al., 2003a). One 
out of eight melanoma patients presents with brain metastasis at stage IV diagnosis (Tas, 
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2012). This fraction increases to three out of four metastatic melanoma patients at 
autopsy (Amer et al., 1978; Patel et al., 1978). Brain metastasis bodes very unfavorably 
for prognosis in melanoma and overall survival time ranges between 4-9 months after 
diagnosis (Davies et al., 2011; Fife et al., 2004). 
The morbidity and mortality associated with melanoma brain metastasis are most 
often attributed to hemorrhage and increased intracranial pressure. Among all brain 
malignancies, melanoma brain metastases have the highest risk of hemorrhage with 27-
40% of all intracranial lesions showing active hemorrhage on neuroimaging and up to 
71% of patients with melanoma brain metastases showing evidence of prior hemorrhage 
by histopathology (Ewend et al., 1996; Marek and Ehud, 2000).  In addition to the 
hemorrhage, brain metastases are associated with other complications such as 
hydrocephalous from obstructed flow of cerebrospinal fluid and local mass effect by 
tumor expansion (Chaichana and Chaichana, 2011). These complications place the 
patient at risk for increased intracranial pressure and commonly manifest as headaches, 
nausea, mental status change, vomiting, cranial nerve palsies, visual deficits, hemiparesis, 
and sensory loss (Ewend et al., 1996). Focal and generalized seizures are also common 
sequelae of brain metastases and further add to the morbidity of this complication.    
Current clinical therapy for melanoma brain metastasis can be divided into three 
broad categories: palliative, definitive, and investigational (Chaichana and Chaichana, 
2011; Gorantla et al., 2013). Palliative care includes steroids to reduce inflammation 
caused by hemorrhage and edema, anticonvulsants to combat seizures secondary to the 
metastatic lesion, and anticoagulants to prevent postoperative thromboembolic disease. 
Definitive therapy includes radiation, either whole brain radiation therapy or stereotactic 
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radiosurgery, surgical resection, and chemotherapy (Eichler and Loeffler, 2007). 
Investigational therapies encompasses the recently approved targeted and immune 
therapies, which show great promise (Flanigan et al., 2011).  
General recommendations for a particular definitive therapy are based on several 
criteria including the size of the brain metastasis, the location of the brain metastasis, and 
the presence of other brain metastases (Chaichana and Chaichana, 2011; Goulart et al., 
2011). Other important factors include the presence and/or extent of extra-cranial 
metastases and the overall health of the patient. The median overall survival of brain 
metastasis patients opting out of definitive therapy is approximately 1-2 months 
(Sampson et al., 1998). Melanoma is notoriously radio-resistant and thus, surgical 
resection is recommended if the metastasis is solitary or limited in number and located in 
a surgically accessible area (Barranco et al., 1971). Immediate tumor de-bulking, 
definitive targeting of the lesion, and histological analysis of resected tissues are all 
advantages of surgical resection. Melanoma brain metastasis patients who are candidates 
for surgical resection and initially receive this treatment have a median overall survival of 
9.83 months (Davies et al., 2011). Patients with multiple melanoma brain metastases or 
disseminated carcinomatous cell spreading in the brain also known as “military 
metastases” are not surgical candidates and are recommended alternative therapies such 
as radiation and chemotherapy. Radiation for melanoma brain metastases can be 
administered in a targeted and nontargeted fashion. Stereotactic radiosurgery is a targeted 
approach that involves the administration of a single fraction of ionizing radiation via 
several converging beams of radiation onto a targeted site. The use of multiple beams of 
radiation from various sources all targeting the same area has been demonstrated to 
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minimize extraneous exposure and mitigate the undesired side-effects of radiotherapy 
(Nieder et al., 2014). Melanoma patients recommended to receive stereotactic 
radiosurgery and initially treated with this modality have a median overall survival of 
7.69 months (Davies et al., 2011). Whole brain radiation therapy is untargeted over the 
entire brain and is particularly useful for treating undetectable micro-metastases or when 
the number of brain metastases is such that it precludes a targeted approach (Khan and 
Dicker, 2013). Despite the many possible side-effects including cognitive dysfunction, 
whole brain radiation improves clinical outcomes and melanoma brain metastasis patients 
receiving this therapy have a median survival of 3.86 months (Davies et al., 2011). 
Standard chemotherapy for metastatic melanoma in the brain has not proven very 
effective. Temozolamide, fotemustine, and thalidomides are used clinically in 
combination or alone but have very low response rates ranging between 7-10% and 
patients receiving chemotherapy alone to treat melanoma brain metastases have a median 
overall survival of 4.64 months (Agarwala et al., 2004; Avril et al., 2004; Chaichana and 
Chaichana, 2011; Davies et al., 2011).  
Targeted therapies are not standard of care for treatment of melanoma brain 
metastasis, but anecdotal evidence suggests these therapies could have clinical utility and 
should be considered for further investigation (Flanigan et al., 2011). A pilot study 
investigating BRAF inhibition and melanoma brain metastasis reported a response rate of 
90% (9/10 patients) in terms of reduced size of brain lesions prompting follow-up studies 
(Falchook et al., 2012). Additional study with a larger patient cohort reported a response 
rate of 39%  in melanoma brain metastasis patients with the BRAFV600E mutation treated 
with dabrafenib, a BRAF inhibitor, and median progression free survival and overall 
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survival of 16 months and 33 months, respectively (Long et al., 2012). However, a 
different study found 19% of melanoma patients without brain metastases given the 
BRAF inhibitor vemurafenib actually develop brain metastases as the only site of 
metastasis while on this targeted therapy (Kim et al., 2011). These contradictory 
outcomes underlie the need for additional clinical studies on the use of targeted therapies 
for melanoma brain metastases. 
Immune-based therapies have yielded very promising results in melanoma and 
these therapies are currently under investigation for melanoma brain metastases. A 
retrospective study found that two out of seven melanoma patients with untreated brain 
metastases had a complete response to IL-2 treatment (Guirguis et al., 2002). Another 
retrospective review reported that two out of fifteen melanoma patients with brain 
metastases showed a complete response to IL-2 (Powell and Dudek, 2009). Adoptive cell 
transfer (ACT) of tumor-infiltrating lymphocytes has generated significant interest in 
melanoma therapy and has been demonstrated to have efficacy against brain metastases 
(Hong et al., 2010; Vonderheide and June, 2014). In brief, T cells from a melanoma 
patient are harvested from their tumor tissue, selectively expanded with or without further 
genetic manipulation and after patient lympho/myelo-depletion are re-introduced into the 
patient. This form of therapy has generated encouraging results reporting complete 
responses in seven patients and partial responses in six patients out of a total of seventeen 
melanoma patients with brain metastases that received ACT therapy (Hong et al., 2010). 
Check-point inhibitors represent a new class of immune-based therapies comprised of 
antibodies against specific immune-modulating molecules that regulate the amplitude and 
duration of T cell responses (Pardoll, 2012).   Currently, there are two molecules targeted 
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by clinically available check-point inhibitors: Cytotoxic T-lymphocyte protein 4 (CTLA-
4) and Programmed cell death protein 1 (PD-1) (Ott et al., 2013; Webster, 2014). Check-
point inhibitors have demonstrated significant clinical benefit in the treatment of 
metastatic melanoma (Brahmer et al., 2012; Hamid et al., 2013; Hodi et al., 2010; 
Topalian et al., 2012). Anti-PD-1 therapies (pembrolizumab and nivolumab) are a more 
recent development and data on the effectiveness of PD-1 inhibition against melanoma 
brain metastases is currently pending. However, anti-CTLA-4 therapy (ipilimumab) was 
shown through retrospective analysis of phase II data to have some efficacy against brain 
metastases (Schartz et al., 2010; Weber et al., 2011). More impressive have been reports 
of CTLA-4 blockade combined with other therapies such as fotemustine and stereotactic 
radiosurgery yielding disease control in 50% of patients and extending median survival 
from 4.9 months to 21.3 months with these combinations, respectively (Di Giacomo et 
al., 2012; Knisely et al., 2012).  
Although the benefits of recent therapeutic breakthroughs have trickled down and 
improved clinical outcomes for melanoma brain metastasis (Flanigan et al., 2011), large 
advances in this field remain elusive (Gorantla et al., 2013). This reflects the fact that 
brain metastasis is one of the least understood aspects of melanoma (Filder et al., 1999; 
Yashin et al., 2013). One of the key unanswered questions in melanoma brain metastasis 
is “How does melanoma colonize the brain?” The molecular mechanisms that facilitate 
the establishment of melanoma in the brain are not well understood. A significant focus 
of this dissertation is to explore the role of aberrant AKT signaling in promoting 
melanoma brain metastasis.  
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1.9 Mechanisms of Melanoma Brain Metastasis 
Recent imaging work by the Winkler lab described in vivo melanoma brain 
metastasis formation over the course of several sequential steps and shed light on 
necessary processes during brain colonization (Kienast et al., 2010). Using a mouse with 
a chronic cranial window, a multiphoton laser scanning microscope, and fluorescently 
labeled melanoma cells, they identified four steps a mobile, would-be metastatic cell 
follows in order to establish itself as a bona fide brain metastasis: arrest at vascular 
branch point, early extravasation, persistent close contact to microvessels and 
perivascular growth by vessel co-option. Using these steps as a frame work for brain 
metastasis, we will discuss mechanisms implicated in melanoma’s colonization of the 
brain. 
Arresting at intracranial vascular branch points implies that a mobile cell could be 
directed in its migration to the brain by external cues like chemokines or brain-specific 
ligands. Interestingly, expression of the chemokine receptor CCR4 is significantly greater 
in a brain-metastasizing melanoma cell line compared with a non-brain metastasizing 
counterpart (Izraely et al., 2010). Follow up studies revealed that brain-derived soluble 
factors upregulate CCR4 in melanoma cells and specifically enhance cell migration in 
brain-metastasizing melanoma cells (Klein et al., 2012). Endothelin receptor B (EDBRB) 
is another molecule that could drive melanoma’s preferential colonization of the brain. 
Cruz-Munoz et al. demonstrated using a xenograft mouse model of melanoma brain 
metastasis that EDNRB overexpression enhanced the metastatic potential of the 
implanted tumor cells and resulted in more brain metastases compared with control tumor 
cells (Cruz-Munoz et al., 2012). Specifically blocking the EDNRB receptor negated the 
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enhanced metastatic phenotype and resulted in an increased overall survival in the mice. 
The fact that EDNRB ligand is highly expressed in the brain (Firth and Ratcliffe, 1992), 
supports the idea that EDNRB-mediated signaling could drive preferential metastasis to 
the brain. In the mid-1970s, researchers noted that melanoma cells had a very high 
density of receptors for and strong affinity towards nerve growth factor (NGF), opening 
up the idea that a ligand receptor interaction could be the basis for melanoma’s 
predilection for brain metastasis (Fabricant et al., 1977). Subsequent studies determined 
that p75NTR, a receptor for NGF is highly upregulated in melanoma cells and associated 
with brain metastasis (Herlyn et al., 1985; Herrmann et al., 1993). Other receptors such as 
TrkC, the putative receptor for neurotrophin-3 (NT-3) is also highly expressed on 
melanoma cells, providing more evidence that neurotrophins may play a homing role in 
melanoma brain metastasis (Marchetti et al., 2003b). Interestingly, astrocytes found at the 
stromal-tumor interface of melanoma brain metastases display increased expression of 
neurotrophins like NGF and NT-3, further supporting the hypothesis that these ligands 
originate from the brain and attract melanoma cells (Marchetti et al., 1995; Yoshida and 
Gage, 1992).   
The blood-brain barrier (BBB) presents a formidable border that tumor cells must 
cross in order to establish residence in the brain. The BBB is composed of cerebral 
endothelial cells connected together by tight junction proteins and reinforced by a 
relatively thick basement membrane plus an underlying layer of astrocytes (Abbott et al., 
2010). One of the main functions of the BBB is to strictly regulate the flow of ions, 
nutrients, and cells into the brain parenchyma. Several mechanisms have been implicated 
in promoting extravasation through the BBB in melanoma brain metastasis. Stoletov et 
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al. recently demonstrated that melanoma cells utilize the gap junction protein Connexin-
26 (Cx26) to associate with cerebral vasculature during the initiation of brain metastasis 
(Stoletov et al., 2013). Silencing of Cx26 in melanoma cells inhibits extravasation and in 
vivo brain colonization (Stoletov et al., 2013). Heparanase (HPSE) is an enzyme that 
degrades heparan sulfate chains of proteoglycans enriched in endothelial cell layers and 
several lines of evidence suggest HPSE may act in a brain-specific manner allowing 
penetration of the blood-brain barrier by metastatic melanoma cells (Marchetti, 2002; 
Marchetti et al., 2000; Murry et al., 2006). The presence of HPSE increases invasion of 
melanoma cells into brain tissues in brain slice models (Murry et al., 2006). Furthermore, 
co-incubation of brain metastatic melanoma cells with astrocytes results in elevated 
HPSE activity and increased invasive phenotype in vitro (Marchetti et al., 2000). The role 
of HPSE in brain-specific metastasis is further supported by the fact that neurotrophins 
such as NGF enhance HPSE activity (Marchetti et al., 1993). Pleckstrin homology 
domain-containing family A member 5 (PLEKHA5) is a recently described candidate to 
emerge from integrated comparisons of clinical melanoma samples and cell lines with a 
brain homing phenotype (Jilaveanu et al., 2014). PLEKHA5 expression in melanoma 
patients was associated with decreased brain metastasis free survival, defined as the 
elapsed time from diagnosis of first distant metastasis to diagnosis of brain metastasis. In 
vitro studies revealed that PLEKHA5 silencing decreased melanoma cell survival and 
inhibited transmigration through an artificial BBB, suggesting that PLEKHA5 plays a 
role in viability and extravasation into the brain parenchyma.  
Securing access to the blood supply is a critical process for melanoma to establish 
residence in the brain and is carried out in two steps - persistent close contact to 
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microvessels and perivascular growth by vessel co-option (Kienast et al., 2010). 
Mentioned previously for being involved in extravasation, Cx26 is also implicated in 
vessel co-option during melanoma metastasis to the brain (Stoletov et al., 2013). Stat3 
activation has been implicated in promoting brain metastasis by stimulating vascular 
remodeling through increased expression of basic fibroblast growth factor (bFGF), 
vascular endothelial growth factor (VEGF), and matrix metalloproteinase-2 (MMP-2) 
(Xie et al, 2006, Huang et al 2008). Interestingly, the PI3K-AKT pathway, discussed in 
more detail in the following section, is connected to vascular co-option and angiogenesis 
via its role in regulating VEGF, HIF1α, and ANG2 (Ju et al., 2014; Karar and Maity, 
2011; Phung et al., 2015; Phung et al., 2006). 
1.10 AKT Signaling and Melanoma Metastasis 
 Aberrant AKT signaling is observed in up to 70% of melanomas and is associated 
with disease progression (Dai et al., 2005; Davies et al., 2009; Smalley, 2009).	
Phosphorylation at Ser473 and Thr308 induces AKT activation and phosphorylated AKT 
is known to progressively accumulate in lesions undergoing melanomagenesis, with 
especially high levels in metastatic tissues (Dai et al., 2005; Stahl et al., 2004). 
Furthermore, over-expression of AKT in a radially growing melanoma cell line conferred 
an invasive, vertical growth phenotype when subcutaneously implanted in mice 
(Govindarajan et al., 2007).  Clinical data strongly suggest that AKT signaling is 
involved in melanoma metastasis to the brain (Dai et al., 2005; Davies et al., 2009).  A 
comparison between lung, liver, and brain metastases from human melanoma samples 
found significantly higher levels of phosphorylated-AKT and a downstream target, 
21	
phosphorylated-GSK3β, in brain metastases compared to lung and liver metastases 
(Davies et al., 2009). In line with increased AKT activity, PTEN levels were significantly 
lower in brain metastases compared with lung and liver metastases. Follow-up studies 
comparing patient-matched brain versus extracranial melanoma metastases yielded 
additional evidence supporting increased AKT activity as a defining feature of brain 
metastasis (Chen et al., 2014; Niessner et al., 2013). In addition, the loss of PTEN protein 
expression in melanoma patient lymph node metastases is associated with significantly 
shorter time to brain metastasis but not with other organ metastases (Bucheit et al., 2014). 
Although these lines of evidence strongly implicate the involvement of AKT signaling in 
melanoma brain metastasis, the role of aberrant AKT activation in this capacity has not 
been directly tested in vivo.    
1.11 Animal Models of Melanoma Brain Metastasis 
A major obstacle in studying melanoma brain metastasis has been the lack of an 
animal model that mimics the metastatic patterns observed in the human disease. Cruz-
Munoz et al. described a model engineered by sub-dermal injection of severe-combined 
immune-deficient (SCID) mice with metastatic human melanoma cells (Cruz-Munoz et 
al., 2008). Other models have employed intra-carotid or intra-cardiac injection of 
melanoma cells into similar immune-compromised mice (Fujimaki et al., 1993; Morsi et 
al., 2013). Drews and coworkers injected chick embryos with melanoma cells in the 
rhombencephalic brain vesicles to investigate their invasive growth in this environment 
(Busch et al., 2012). While these models have provided valuable information regarding 
specific steps in melanoma metastasis, none described to date arise spontaneously in 
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immunocompetent animals and proceed through every step of the metastatic cascade. 
1.12 Conclusions 
Melanoma is a very aggressive cancer that arises from melanocytes. While 
melanoma is a disease of several subtypes defined by distinct clinical presentations and 
genetic mutations, a universal characteristic of melanoma is its inherent capacity to 
metastasize. Genetic insights have led to new targeted therapies and recent therapeutic 
breakthroughs with immune therapies have shifted the treatment paradigm of metastatic 
melanoma. However, despite the clinical progress, melanoma brain metastasis remains a 
serious concern due to the high mortality and morbidity associated with this 
complication. The mechanisms driving melanoma to the brain are not well understood 
and animal models recapitulating the steps of melanoma brain metastasis are lacking. 
Therefore, to develop breakthrough therapeutics for melanoma brain metastasis, we must 
investigate the molecular pathways promoting disease progression and develop better 
animal models that faithfully mimic the spread of melanoma to the brain similar to the 
human disease. 
1.13 Preview 
The work presented in this dissertation investigates the role of aberrant AKT 
activation in melanoma development and progression. Based on several studies 
implicating elevated AKT signaling in melanoma metastasis to the brain, we examine the 
in vivo role of activated and wild-type AKT1, AKT2, and AKT3 as well as mutant 
AKT3E17K in promoting melanoma spread in a non-metastatic BRAFV600E/INK4A-
ARFNull mouse model of melanoma. We report highly penetrant melanomas with 
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development of spontaneous lung and brain metastases after a relatively short latency. To 
our knowledge, this is the first in vivo melanoma model described that develops 
spontaneous brain metastases. Our findings also demonstrate unexpected differences in 
metastatic potential between melanomas with PTEN silencing versus AKT1 activation, 
and between melanomas expressing different activated AKT isoforms and AKT3E17K. 
Upregulation of mTOR signaling downstream of AKT activation is implicated in 
promoting melanoma brain metastasis. In addition to the molecular mechanisms 
examined, our in vivo model provides a valuable tool to further understand the biology of 
melanoma brain metastasis and to evaluate therapeutic strategies aimed at preventing and 
treating these deleterious lesions.   
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CHAPTER 2 
AKT1 ACTIVATION PROMOTES THE DEVELOPMENT OF  BRAIN 
MELANOMA METASTASES 
2.1 Preface 
This chapter is a re-formatted version of a manuscript submitted to Cell Reports 
in April 2015. The work presented herein was completed with the following co-authors:  
James P. Robinson, Rowan A. Arave, Russell D. Green, David A. Kircher, Guo Chen, 
Michael A. Davies, Allie H. Grossmann, Matthew W. VanBrocklin, Martin McMahon, 
and Sheri L. Holmen. 
2.2 Introduction 
 Recent approvals of more efficacious therapies have shifted the treatment 
paradigm for melanoma and have provided much needed breakthroughs in this disease 
(Girotti et al., 2014). However, the increasing incidence of melanoma and the mortality 
associated with advanced stages of the disease remain cause for concern. More than half 
of all melanoma deaths are due to brain metastases (Davies et al., 2011), which are one of 
the most common and devastating complications of melanoma. Up to 75% of patients 
with stage IV melanoma will develop brain metastases and the prognosis for these 
patients is extremely poor (Chaichana and Chaichana, 2011). Despite recent therapeutic  
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advances, melanoma brain metastasis continues to pose a significant clinical 
challenge and demands further investigation into the molecular mechanisms 
driving distant dissemination of this disease.  
 Clinical data provides compelling correlative evidence that AKT signaling is 
involved in melanoma metastasis, especially to the brain (Dai et al., 2005; Davies et al., 
2009).  A comparison between lung, liver, and brain metastases from human melanoma 
samples noted significantly higher levels of phosphorylated AKT and a downstream 
target, phosphorylated GSK3β, in brain metastases compared to lung and liver 
metastases. In line with increased AKT activity, PTEN protein levels were significantly 
lower in brain metastases compared with lung and liver metastases (Davies et al., 2009; 
Niessner et al., 2013). Follow-up studies comparing patient-matched brain versus 
extracranial melanoma metastases found additional evidence of increased AKT activity 
as a feature of brain metastases but PTEN protein levels were similar between the 
matched metastases (Chen et al., 2014). Furthermore, PTEN silencing combined with 
expression of BRAFV600E in mouse melanocytes in vivo resulted in melanoma formation 
and development of lymph node and lung metastases but not brain metastases (Dankort et 
al., 2009).  
 PTEN is a phosphatase with activity against both lipid and protein substrates 
(Chalhoub and Baker, 2009). Its major substrate is phosphatidylinositol-3,4,5-
triphosphate (PIP3), which binds to AKT via its pleckstrin homology (PH) domain and 
acts to recruit AKT to the membrane where it is activated through phosphorylation by 
phosphoinositide-dependent kinase 1 (PDK1) and the mammalian target of rapamycin 
complex 2 (mTORC2). PTEN specifically dephosphorylates the 3ʹ position of PIP3 to 
create phosphatidylinositol-4,5-bisphosphate (PIP2) and thereby suppresses membrane 
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recruitment and downstream signaling of AKT. Loss of PTEN results in increased levels 
of PIP3 and subsequent AKT activation. However, several studies suggest that PTEN loss 
does not phenocopy AKT activation (Ackler et al., 2002; Li et al., 2002; Majumder et al., 
2003; Marsh Durban et al., 2013; Wang et al., 2003). Furthermore, the effects of 
activated AKT in the context of aberrant mitogen-activated protein kinase (MAPK) 
signaling have not been directly assessed in a mouse model of spontaneous melanoma 
metastasis.  
 In this study we describe the first in vivo melanoma model that develops both 
spontaneous lung and brain metastases similar to the human disease. Using an established 
mouse model of melanoma that allows postnatal gene delivery to somatic cells, we 
assessed the ability of PTEN silencing or AKT1 activation, either alone or in 
combination, to promote melanomagenesis and metastasis in the context of mutant 
BRAFV600E and silencing of INK4A and ARF. While both PTEN silencing or expression 
of activated AKT1 promoted melanoma formation in this context, only melanomas with 
activated AKT1 developed spontaneous brain metastases. Additionally, PTEN silencing 
cooperated with active AKT1 to accelerate both tumor formation and metastasis. Further 
analysis of the differences between these tumors revealed activation of mTORC signaling 
in tumors driven by activated AKT, further supporting a role for this pathway in 
melanoma metastasis (Damsky et al., 2015; Liu et al., 2012). This model provides a 
valuable tool to further define the mechanisms that promote melanoma metastases to the 
brain and a powerful platform to advance the development of anti-melanoma therapies. 
Our findings demonstrate distinct differences in the metastatic potential of melanomas 
with AKT1 activation versus PTEN silencing and may provide valuable insights for 
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assessing risk for the development of melanoma brain metastases and for guiding clinical 
treatment.  
2.3 Results 
2.3.1 BRAFV600E/INK4A-ARFNull melanomas are not metastatic. To evaluate 
melanoma metastasis in the context of specific genetic alterations, we utilized an 
established melanoma mouse model based on the RCAS/TVA system that allows for 
targeted delivery of specific genes to post-natal melanocytes (VanBrocklin et al., 2010). 
This system utilizes a viral vector, RCASBP(A), hereafter referred to as RCAS, and its 
receptor TVA. Transgenic mice that express TVA under the control of the dopachrome 
tautomerase (DCT) promoter allow targeting of the virus, and expression of the genes it 
contains, specifically to melanocytes. To assess metastasis using this model in the context 
of mutationally activated BRAFV600E, we compound generated 
Dct::TVA;BRafCA;Cdkn2alox/lox mice (VanBrocklin et al., 2010) carrying a conditional 
Cre-activated allele of Braf.  The BrafCA allele expresses wild-type BRAF prior to Cre-
mediated recombination after which BRAFV600E is expressed from the normal 
chromosomal locus (Dankort et al., 2007).  The Cdkn2alox allele expresses normal 
INK4A and ARF prior to Cre-mediated recombination after which expression of both 
p16INK4A and p19ARF is extinguished. (Aguirre et al., 2003).  
 Newborn Dct::TVA;Braf CA;Cdkn2alox/lox mice were injected subcutaneously with 
a RCAS virus encoding Cre to induce BRAFV600E expression with concomitant silencing 
of INK4A and ARF in melanocytes. While BrafCA; Cdkn2alox/lox mice lacking Dct::TVA 
injected with RCAS:Cre remained tumor free for the duration of the study (150 days, n = 
42 
40), 47% (16/34) of the Dct::TVA;Braf CA; Cdkn2alox/lox mice infected with the 
RCAS:Cre virus developed tumors at the site of injection (Table 2.1). The mean survival 
for tumor-bearing mice in this cohort was 88.9 ± 8.6 days (Figure 2.1). All major organs 
were examined at euthanasia but no melanoma metastases were observed in any of the 
tumor-bearing mice.  
 2.3.2 PTEN silencing increases tumor incidence and reduces tumor latency but 
does not enhance metastasis. Because BRAFV600E  cooperates with PTEN silencing to 
induce metastatic melanoma (Dankort et al., 2009), we generated 
Dct::TVA;BrafCA;Cdkn2alox/lox;Ptenlox/lox (Ptenlox/lox) mice. The Ptenlox allele used here 
expresses normal PTEN prior to Cre-mediated recombination after which deletion of the 
exon 5 sequence generates a Pten null allele (Zheng et al., 2008). Newborn 
Dct::TVA;BrafCA;Cdkn2alox/lox;Ptenlox/lox mice were injected subcutaneously with 
RCAS:Cre to induce BRAFV600E with concomitant silencing of INK4A, ARF and PTEN 
in melanocytes. Importantly, control mice, BrafCA;Cdkn2alox/lox;Ptenlox/lox lacking 
Dct::TVA infected with RCAS:Cre remained tumor free for the duration of the study (150 
days, n = 40). Tumors developed at the site of injection in all of the Dct::TVA-positive 
BrafCA;Cdkn2alox/lox;Ptenlox/lox mice infected with RCAS:Cre viruses (24/24;  Figure 2.1 
and Table 2.1). The mean survival was 57.8 ± 3.4 days in this cohort (Figure 2.1). 
Expression of Cre was assessed by RT-PCR (Figure 2.2A) and recombination of Ptenlox 
was confirmed by PCR in all of the tumors that developed (Figure 2.2B). In these mice, 
lung metastases were detected in 8.3 % (2/24) of the mice whose melanomas had PTEN 
silencing. However, using a Fisher’s exact test we determined that this difference was not 
significant when compared with mice whose tumors expressed PTEN (P = 0.5).  
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2.3.3 Expression of activated AKT1 promotes melanoma formation and 
metastasis. Several studies have shown that PTEN silencing confers a different 
phenotype than AKT activation (Majumder et al., 2003; Wang et al., 2003). Therefore, 
we evaluated the effect of mutationally activated AKT1 on melanoma formation and 
progression in vivo. Newborn Dct::TVA;BrafCA;Cdkn2alox/lox (PtenWT) mice were injected 
subcutaneously with RCAS viruses encoding myristoylated (myr) Akt1 alone or in 
combination with viruses encoding Cre. While Dct::TVA;BrafCA;Cdkn2alox/lox mice 
injected with viruses encoding myrAkt1 alone remained tumor free for the duration of the 
study (150 days, n = 21), 88% (24/27) of the mice injected with both myrAkt1 and Cre 
encoding viruses developed tumors at the site of injection (Figure 2.1 and Table 2.1). The 
mean survival of the tumor-bearing mice in this cohort was 65.3 ± 4.7 days (Figure 2.1). 
It is important to note that AKT1 expression is not required for tumor formation in the 
context of BRAFV600E/INK4A-ARF silencing; tumors develop in nearly half 
of Dct::TVA;Braf CA;Cdkn2alox/lox mice infected with viruses encoding Cre only 
(Figure 2.1). Of the 24 mice that developed tumors when injected with myrAkt1 and Cre 
viruses, AKT1 expression was detected in 18 of the tumors by IHC for the HA 
epitope tag on myrAKT1 (Figure 2.3). The mean survival was 58.9 ± 3.5 in this 
myrAKT1-confirmed cohort (Figure 2.4 and Table 2.1). A significant difference in 
survival was observed between mice whose tumors expressed myrAKT1 and those 
without myrAKT1 (P = 2.3 x 10-9). A significant difference in survival was also 
observed between the Ptenlox/lox cohort injected with viruses encoding Cre only when 
compared with all of the mice in the PtenWT cohort injected with two separate viruses 
encoding Cre and myrAkt1  (P = 0.045) (Figure 2.1 and Table 2.1). However, 
comparison between the mice whose tumors were found  to  express  myrAKT1 by  IHC 
44 
(18/24) and mice whose tumors lacked PTEN revealed no significant difference in 
survival (P = 0.994; Figure 2.4). All major organs were examined in tumor-bearing 
mice. Interestingly, lung metastases were observed in 67% (12/18) and brain metastases 
were observed in 17% (3/18) of the mice whose tumors expressed myrAKT1. This 
difference was statistically significant when compared with both the PtenWT and the 
Ptenlox/lox cohorts injected with RCAS:Cre viruses (P < 0.0001).  
2.3.4 PTEN silencing cooperates with activated AKT1 to accelerate 
melanomagenesis and to promote metastasis. Our data revealed differences in the 
development of metastases between cohorts of mice whose tumors lacked PTEN 
compared with mice whose tumors expressed myrAKT1. Therefore, we assessed whether 
PTEN silencing could cooperate with myrAKT1 activation to promote melanoma 
formation and progression. To test this, newborn Dct::TVA; BrafCA;Cdkn2alox/lox;Ptenlox/lox 
mice were injected subcutaneously with viruses encoding myrAkt1 and Cre. Tumors 
developed at the site of injection in all of the mice in this cohort (14/14) and myrAKT1 
expression was detected in all of these tumors by anti-HA IHC (Figure 2.5). Expression 
of Cre was assessed by RT-PCR (Figure 2.6A) and recombination of Pten was confirmed 
by PCR in all of the tumors that developed (Figure 2.6B). Interestingly, melanomas with 
concomitant PTEN silencing and myrAKT1 expression had significantly reduced 
survival compared with mice whose tumors only had PTEN silencing (P = 0.0009) or 
expressed myrAKT1 in the presence of PTEN (P = 0.0002). The mean survival in this 
cohort was 42.1 ± 2.8 days (Figure 2.4 and Table 2.1). All major organs were examined 
and lung and brain metastases were observed in 71% (10/14) and 79% (11/14) of the 
mice, respectively. A comparison of the sites of metastases revealed no significant 
difference in lung metastases (P = 1.0) but there was  a  statistically significant  difference
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in brain metastases between tumors driven by myrAKT1 in the presence or absence of 
PTEN (P = 0.0009). 
2.3.5 Histological characterization of the mouse melanomas reveals features 
similar to the human disease. Melanomas arising in Dct::TVA;BrafCA;Cdkn2alox/lox mice 
infected with both RCAS:Cre and RCAS:myrAkt1 encoding viruses consisted primarily 
of short spindle cells, occasional epithelioid cells, and with high grade nuclear features 
prominent nucleoli. Intratumoral hemorrhage, coagulative tumor necrosis, and non-brisk 
inflammation (tumor infiltrating lymphocytes) were variably noted (Figure 2.7A). Mitotic 
figures were abundant and the majority of the cells expressed the Ki67 proliferation 
marker (Figure 2.7B). The activity of BRAFV600E was assessed by IHC for pERK as 
a surrogate (Figure 2.7C). The melanocytic origin of these tumors was established by 
their immunoreactivity for a pan-melanoma cocktail consisting of antibodies to 
HMB-45, a pre-melanosomal glycoprotein gp100, and melanoma antigen recognized 
by T-cells-1 (MART-1) (Figure 2.7D). The combination of positivity for both HMB-45 
and MART-1 is highly supportive of a melanoma diagnosis (Ohsie et al., 2008).  
Upon gross examination, lesions were visible on the surface of the lungs 
(Figure 2.7E) and microscopic examination confirmed the morphologic features of 
malignancy (Figure 2.7F-G). AKT1 expression was detected in the metastases by IHC 
for the HA epitope tag on myrAKT1 (Figure 2.7H). Brain metastases were also 
observed in Dct::TVA;BrafCA;Cdkn2alox/lox mice infected with both Cre and myrAkt1 
containing viruses (Figure 2.7I). Expression of myrAKT1 was confirmed in the brain 
metastases by IHC for the HA tag on virally delivered myrAKT1 (Figure 2.7J). 
Primary tumors from each of the cohorts described above were assessed for the 
presence    of     phosphorylated     AKT    (pS473)     by     IHC     and     compared     with
46 
BRAFV600E/INK4A-ARFNull melanomas (Figure 2.8A-B). As expected, active 
pS473-AKT was detected in tumors lacking PTEN, expressing myrAKT1, or both 
(Figure 2.8C-H). The levels of pS473-AKT were also assessed by immunoblot 
analysis of lysates generated from fragments of tumors lacking PTEN, expressing 
myrAKT1, or both (Figure 2.9). In agreement with the IHC data, PTENNull 
melanomas displayed higher levels of pS473-AKT (Figure 2.10). Expression of 
myrAKT1 was confirmed by immunoblotting for the HA epitope tag on 
myrAKT1. Cre-mediated expression of mutationally activated BRAF was assessed 
using an antibody specific for BRAFV600E. Activity of the MAPK pathway was 
assessed by analysis of phosphorylated ERK expression. Total levels of ERK were 
similar between the samples. As expected, the level of total AKT was higher in the 
melanomas engineered to express myrAKT1 and a wider band representing the larger 
molecular mass of myrAKT1 was detected on the total AKT blot (Figure 2.9).  
2.3.6 Reverse-phase protein array analysis revealed increased mTOR signaling 
in tumors expressing myrAKT1. To define differences in signaling between the 
melanomas lacking PTEN and those expressing myrAKT1 in a high-throughput manner 
we used a reverse-phase protein array (RPPA) approach. RPPA allows quantitative 
analysis of protein levels and activation using small amounts of protein (Liotta et al., 
2003). Tumor-enriched protein isolates from five PTENNull and four 
myrAKT1-expressing melanomas were analyzed by RPPA. The heat-map in Figure 
2.11 shows the results of unsupervised hierarchical clustering of the results of this 
analysis, which showed a significant difference in protein modification/expression levels 
(n=11; P < 0.05 by unpaired t-testing) between the five PTENNull tumor samples and the 
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four myrAKT1-expressing melanoma samples. A list of all 131 epitopes assessed with 
their respective P-values is presented in Table 2.2. As expected, lower levels of PTEN 
expression were detected in the melanoma samples from Ptenlox/lox mice. In agreement 
with both the IHC and immunoblot analyses, a higher level of pS473-AKT was 
observed in the PTENNull tumor samples. Interestingly, components of the 
mammalian target of rapamycin (mTOR) signaling pathway (e.g., RAPTOR, 
RICTOR, NF2 and MYH11) were significantly different between the two groups 
(Figure 2.11 and Figure 2.12). 
2.4 Discussion 
 In this study we describe the first in vivo melanoma model that develops both 
spontaneous lung and brain metastases similar to human melanoma. A major obstacle in 
studying melanoma brain metastasis has been the lack of an animal model that mimics 
the metastatic patterns observed in the human disease. Cruz-Munoz et al. described a 
model engineered by sub-dermal injection of severe combined immunodeficiency (SCID) 
mice with metastatic human melanoma cells (Cruz-Munoz et al., 2008). Other models 
have employed intra-carotid or intra-cardiac injection of melanoma cells into 
immunocompromised mice (Fujimaki et al., 1993; Morsi et al., 2013). Drews and 
coworkers injected chick embryos with melanoma cells in the rhombencephalic brain 
vesicles to investigate their invasive growth in that environment (Busch et al., 2012). 
While these models have provided valuable information regarding specific steps in 
melanoma metastasis, none represent spontaneous brain metastasis in an animal with an 
intact immune system. Through combined PTEN silencing and mutational activation of 
AKT1 in the context of  the  BRAFV600E  oncoprotein  kinase  and  INK4A-ARF  silencing,
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we have established a model of spontaneous lung and brain metastases that displays high 
penetrance and short latency. Furthermore, we provide compelling evidence that AKT1 
activation plays a critical role in promoting melanoma brain metastasis in vivo via a 
mechanism that is independent of, yet augmented by, PTEN silencing.     
 We observed dramatically increased metastasis in mice bearing tumors driven by 
activated AKT1 compared with Pten loss. Moreover, AKT1 activation cooperated with 
Pten loss to accelerate tumor formation and further increase metastasis. Taken together, 
these results strongly suggest that Pten loss renders a phenotypically distinct pattern of 
melanoma development and progression from AKT1 activation. Studies in other cancers 
support the findings that PTEN silencing/mutation is not synonymous with AKT 
activation. Mice with prostate-specific PTEN silencing develop invasive prostate cancer 
with a frequency of 40-90%, whereas mice with prostate-specific constitutive activation 
of AKT only develop localized pre-neoplastic lesions (Majumder et al., 2003; Wang et 
al., 2003). In addition, mammary gland-specific PTEN silencing elicits excessive 
branching, accelerated ductal extension and mammary tumors with metastatic potential.  
By contrast, ectopic expression of activated AKT1 in the same context resulted in no 
major differences in ductal growth or epithelial differentiation compared to controls 
(Ackler et al., 2002; Li et al., 2002). Furthermore, the pharmacological inhibition of AKT 
was reported to have little effect on the growth of Pten-deficient melanomas driven by 
BRAFV600E (Marsh Durban et al., 2013). 
Aberrant  AKT  signaling is implicated in several steps of melanoma pathogenesis 
including metastasis (Robertson, 2005). Phosphorylation at Ser473 and Thr308 induces 
AKT activation and phosphorylated AKT levels increase as tumors progress from benign 
nevi  to  metastases  (Chen et al., 2014;  Dai et al., 2005;  Davies et al., 2009;  Stahl et al.,
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 2004). Activation of the PI3K→AKT pathway in melanoma occurs via several 
mechanisms including deletion or inactivation of the negative regulator PTEN, which is 
observed in up to 43% of melanomas, through genomic amplification or increased gene 
expression of AKT (Bastian et al., 1998; Stahl et al., 2004), and activating mutations in 
PIK3CA and AKT isoforms, which occurs in 1-5% and 1-2% of melanomas, respectively 
(Curtin et al., 2006; Davies et al., 2008; Mikhail et al., 2005; Omholt et al., 2006). This is 
consistent with what has been observed in larger studies (Cerami et al., 2012; Hodis et 
al., 2012). Moreover, novel mutations in AKT1 confer a survival advantage for 
melanoma and are often found in the setting of drug-resistant, metastatic disease (Shi et 
al., 2014).  
 Interestingly, PTEN deficient melanomas had significantly higher levels 
of phosphorylated AKT (Figure 2.8D, Figure 2.9, and Figure 2.11) compared with 
tumors expressing myrAKT1 (Figure 2.8F, H, Figure 2.9, Figure 2.11) yet 
significantly fewer metastases. In mammals there are three isoforms of AKT, namely 
AKT1, AKT2 and AKT3. While the AKT isoforms share ~80% amino acid 
sequence identity, in vivo studies demonstrate that they have both redundant and 
non-overlapping functions (Gonzalez and McGraw, 2009). There have been 
conflicting reports regarding which isoforms of AKT are phosphorylated following 
PTEN loss in melanoma cells (Nogueira et al., 2010; Stahl et al., 2004). It is possible 
that signaling from AKT1 differs from the signaling that results from the activation of 
AKT isoforms with PTEN silencing.  Some studies suggest that AKT isoforms have 
opposing functions with regards to tumorigenesis (Linnerth-Petrik et al., 2014; 
Maroulakou et al., 2007). Maroulakou et al. found that Akt1 ablation inhibited, whereas 
Akt2 ablation accelerated, development of mammary  adenocarcinomas  in  two  different 
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mouse models of breast cancer (Maroulakou et al., 2007). Wootton and coworkers 
recently reported similar findings that deletion of Akt1 delayed tumor initiation in a 
murine lung cancer model, while loss of Akt2 and Akt3 significantly accelerated 
tumorigenesis (Linnerth-Petrik et al., 2014). It is possible that specific isoforms of 
AKT differentially contribute to tumor growth and/or metastatic potential in 
melanoma and that activation of AKT2 or AKT3 following PTEN loss may oppose the 
activity of AKT1 resulting in the different phenotypes we observed.  
 In this study we observed significant differences in mTORC pathway components 
between our PTEN deficient versus myrAKT1 expresssing melanomas suggesting a 
disrupted elevation of this signaling pathway. Several lines of evidence provide strong 
support that enhanced mTORC signaling promotes melanoma metastasis.  mTOR is a 
kinase that assembles with accessory proteins to form mTOR complex 1 (mTORC1) or 
mTOR complex 2 (mTORC2) (Laplante and Sabatini, 2012). Specific functions differ 
depending on which mTOR complex forms, however both complexes function toward 
integrating growth factor stimulation and nutrient availability with protein synthesis and 
cell growth. Interestingly, mTORC1 and mTORC2 are functionally connected to one 
another through the PI3KàAKT pathway. Activated AKT turns on mTORC1 by directly 
inhibiting two of its negative regulators, PRAS40 and TSC2 (Inoki et al., 2002; Manning 
et al., 2002; Vander Haar et al., 2007). AKT is also known to inhibit AMP-activated 
protein kinase (AMPK)-mediated positive regulation of TSC2 (Hahn-Windgassen et 
al.,2005). Through a feedback inhibitory mechanism that involves S6K1, a major 
downstream effector of mTORC1, activated mTORC1 turns off AKT signaling by 
inhibiting IRS1, an activator of PI3K (Harrington et al., 2005; Manning, 2004). 
Conversely,  mTORC2  acts   as  a  positive  regulator  of   AKT  by  phosphorylating  the 
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activating AKT residue, Ser473 (Sarbassov et al., 2005).  
 Hyperactive mTORC signaling is disproportionately observed in melanomas 
(73%; 78/107) compared to benign nevi (4%; 3/67) (Karbowniczek et al., 2008). Deletion 
of Lkb1, a known negative regulator of mTORC signaling, in KRas-mutant mouse 
melanocytes results in the formation of highly metastatic melanomas in vivo (Liu et al., 
2012). More recently, loss of Lkb1 in the context of non-metastatic BRAFV600E/INK4A-
ArfNull melanomas resulted in highly metastatic disease (Damsky et al., 2015). The 
pharmacological targeting of mTOR effectively blocks melanoma cell growth in vitro 
and in animal models (Dankort et al., 2009; Guba et al., 2002; Hidalgo and Rowinsky, 
2000). Unfortunately, but not surprisingly, mTOR inhibitors have failed to demonstrate 
clinical efficacy against melanoma as mono-therapy and are currently being evaluated in 
combination with other therapies for this disease (Clinicaltrials.gov, 2015; Margolin et al., 
2005). In line with increased mTORC signaling in melanoma metastasis we found that 
total protein and phospho-protein levels of Rictor, an exclusive mTORC2 component, 
were significantly higher in myrAKT1 expressing melanomas compared to PTEN 
deficient melanomas (Figure 2.11 and Figure 2.12). Taken together, our findings and 
those of others implicate increased mTORC signaling in promoting melanoma metastasis.  
 We report the first in vivo, autochthonous model of melanoma with spontaneous 
metastasis to the lungs and brain. Our data highlights the importance of AKT1 
activationin promoting melanoma metastasis to the brain as well as differences between 
AKT1 activation and PTEN silencing. These data also revealed that PTEN silencing 
cooperates with activated AKT1 to promote melanoma brain metastases with shorter 
tumor latency.  This  model  is  likely to prove useful for further analysis of the biology of
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melanoma metastasis as well as evaluation of specific therapies aimed at preventing 
or treating disseminated disease. 
2.5 Materials and Methods 
2.5.1 Vector constructs. The retroviral vectors in this study are replication-
competent avian leukosis virus, Bryan polymerase-containing vectors of envelope 
subgroup A [designated RCASBP(A) and abbreviated RCAS]. RCAS-Cre and RCAS-
myrAkt1 have been described previously (Aoki et al., 1998; VanBrocklin et al., 2010). 
2.5.2 Cell culture. DF-1 cells were grown in DMEM-high glucose media 
supplemented with 10% FBS (Invitrogen, Waltham, MA USA), 2.5mL Gentamicin 
(Invitrogen), and maintained at 39°C. 
2.5.3 Virus propagation. Virus infection was initiated by calcium phosphate 
transfection of plasmid DNA into DF-1 cells. Viral spread was monitored by GFP 
positive control transfection and expression of the p27 viral capsid protein by Western 
blot. 
2.5.4 Western blotting. Tumor samples were flash frozen in liquid nitrogen and 
pulverized using a mortar and pestle. The pulverized tumor samples were resuspended in 
RPPA buffer (Tibes et al., 2006) with protease and phosphatase inhibitors (Pierce 
Biotechnology, Rockford, IL, USA). Tumor samples in RPPA buffer were diluted in 
SDS-sample buffer and boiled for 10 minutes. The proteins were separated on a 4-20% 
Tris-glycine polyacrylamide gel, transferred to nitrocellulose, and incubated for 1 hour at 
room temperature in blocking solution (0.1% Tween-20 in 1× TBS with 5% nonfat dry 
milk, or 0.1% Tween-20 in 1× TBS with 5% BSA). Blots were immunostained with 
primary antibody at required dilution. All antibodies were diluted in TBS-T solution.  
53 
TBS). The blots were then incubated with an anti-mouse IgG-horseradish peroxidase 
secondary antibody diluted 1:1000 (Sigma-Aldrich Corp., St. Louis, MO, USA) for 1 
hour at room temperature. The blots were washed in TBS-T wash buffer, incubated with 
enhanced chemiluminescence solutions according to the manufacturer's specifications 
(Amersham, Piscataway, NJ USA), and exposed to film. See Supplemental Information 
for a list of primary antibodies used. 
2.5.5 Viral infections in vivo. Infected DF-1 cells from a confluent culture in a 10 
cm dish were trypsinized, pelleted, resuspended in 50 µL PBS, and placed on ice. 
Newborn mice were injected subcutaneously behind the ear. Mice were monitored daily 
for tumor development. Mice received 50 µL of suspended myrAkt1 cells and 50 µL of 
suspended Cre cells. 
2.5.6 Histology and histochemical staining. Mice were euthanized at their 
experimental endpoints set according to the guidelines of the University of Utah 
Institutional Animal Care and Use Committee. Mouse tissues were fixed in formalin 
overnight, cut into three sections, and then dehydrated in 70% ethyl alcohol. Tissues were 
paraffin-embedded and 5µm sections were adhered to glass slides. Sections were stained 
Western blots were incubated in the primary antibody for 1 hour at room temperature 
with constant shaking and then washed in TBS-T wash buffer (0.1% Tween-20 in 1× 
with H&E or left unstained for immunohistochemistry. 
2.5.7 Immunohistochemistry. Tissue sections were hydrated and deparaffinized 
and antigen retrieval was performed in 1× Rodent Decloaker buffer (Biocare Medical, 
Concord, CA USA) by boiling for 20 minutes in a Decloaking Chamber (Biocare 
Medical). Sections were treated with 3% hydrogen peroxide and blocked in Rodent Block 
(Biocare Medical) for 30 minutes. Primary antibodies were diluted in Renaissance 
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background reducing diluent (Biocare Medical). Sections were incubated overnight at 
4°C and probed with Mouse on Mouse HRP polymer reagent (Biocare Medical). 
Visualization was carried out with DAB (Biocare Medical). Sections were counterstained 
with hematoxylin. See Supplemental Information for primary antibodies used. 
2.5.8 Reverse-phase protein array (RPPA). Frozen tumor tissue was embedded in 
optimum cutting temperature (OCT) compound. H&E stained slides were reviewed by an 
experienced dermatopathologist (Alexander J. Lazar) to identify areas that contained 
>70% tumor cells. Regions with extensive necrosis, fibrosis, or hemorrhage within the
tumor specimens were excluded. The H&E slides were used as a guide to macrodissect 
the OCT blocks and isolate tumor-enriched regions for further analysis. Ten to 20 µm 
tumor shears were generated by cryostat and were used for protein and total RNA 
extraction. Proteins were isolated from the tumor shears and RPPA was performed as 
previously described (Davies et al., 2009; Tibes et al., 2006). 
2.5.9 Mice and genotyping. Dct::TVA;Cdkn2alox/lox mice were crossed with 
BrafCA mice to generate Dct::TVA;Cdkn2alox/lox;BrafCA mice (designated as PtenWT). 
Further breeding of PtenWT mice with Ptenlox/lox mice (a gift from Ronald DePinho) 
yielded Dct::TVA;Cdkn2alox/lox;BrafCA; Ptenlox/lox mice (referred to as Ptenlox/lox). DNA 
was prepared from tail biopsies and genotyped by PCR for the Dct::TVA transgene, 
Cdkn2alox, BrafCA, Ptenlox and wild-type alleles as described (Dankort et al., 2007; 
VanBrocklin et al., 2010; Zheng et al., 2008). 
2.5.10 Statistical analysis. Censored survival data was analyzed using a log-rank 
test of the Kaplan-Meier estimate of survival. Densitometry of the Western blot was 
performed using ImageJ (Schneider et al., 2012) and the data is represented as mean ± 
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S.E.M. Student's t test was used to compare protein expression levels between groups in 
the RPPA analysis. Protein-protein coefficients were determined by the Pearson 
correlation method and the significance of the interactions was determined by the t 
statistic using R software. Unsupervised hierarchical clustering of mean-centered protein 
expression values was done using Cluster 2.1 and Treeview software.  
2.5.11 Study approval. All animal experimentation was performed in AAALAC 
approved facilities at the University of Utah. All animal protocols were reviewed and 
approved prior to experimentation by the Institutional Animal Care and Use Committee 
at the University of Utah. 
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Table 2.1 Summary of tumor formation. The mean survival (days) and tumor 
incidence (fraction of tumor-bearing mice per cohort) are listed for each mouse cohort 
according to genetic background and virally delivered genes. 
*HA positive by IHC.





Braf CA;Cdkn2alox/lox Cre 0/40 N/A 
Dct::TVA;Braf CA;Cdkn2alox/lox Cre 16/34 88.9 ± 8.6 
Braf CA;Cdkn2alox/lox;Ptenlox/lox Cre 0/40 N/A 
Dct::TVA;Braf CA;Cdkn2alox/lox;Ptenlox/lox Cre 24/24 57.8 ± 3.4 
Dct::TVA;Braf CA;Cdkn2alox/lox myrAkt1 0/21 N/A 




65.3 ± 4.7 
58.9 ± 3.5 
Dct::TVA;Braf CA;Cdkn2alox/lox;Ptenlox/lox Cre + myrAkt1 14/14 42.1 ± 2.8 
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Table 2.2 Epitopes assessed by RPPA. The 131 epitopes assess by RPPA are listed with 














14-3-3_beta-R-V 0.986899929	 eEF2K-R-V	 0.214172199	 p90RSK_pT359_S363-R-C	 0.52225674	
14-3-3_zeta-R-V 0.107018017	 EGFR-R-V	 0.221429256	 Paxillin-R-C	 0.180331121	
4E-BP1-R-V	 0.936245747	 EGFR_pY1068-R-C	 0.332275723	 PDCD4-R-C	 0.06552092	
4E-BP1_pS65-R-V	 0.070700747	 EGFR_pY1173-R-V	 0.702097331	 PDK1-R-V	 0.192509816	
4E-BP1_pT37_T46-R-
V	 0.99229202	 eIF4E-R-V	 0.111970978	 PDK1_pS241-R-V	 0.663867737	
53BP1-R-E	 0.574164284	 eIF4G-R-C	 0.8369896	 PEA15-R-V	 0.350624594	
ACC_pS79-R-V	 0.230415179	 ER-alpha-R-V	 0.937165972	 PEA15_pS116-R-V	 0.14612053	
ACC1-R-E	 0.194849917	 ER-alpha_pS118-R-V	 0.077818823	 PI3K-p110-alpha-R-E	 0.00164515	
ACVRL1-R-C	 0.613499722	 FASN-R-V	 0.527369196	 PI3K-p85-R-V	 0.184651165	
Akt-R-V	 0.116263529	 Fibronectin-R-V	 0.071035802	 PKC-alpha_pS657-R-E	 0.268995686	
Akt_pS473-R-V	 0.042699831	 FOX03a-R-C	 0.601223343	 PKC-delta_pS664-R-V	 0.890360155	
Akt_pT308-R-V	 0.832904104	 FoxM1-R-V	 0.708119528	
PKC-pan_BetaII_pS660-
R-V	 0.236700005	
AMPK_alpha-R-C	 0.804747501	 Gab2-R-V	 0.683533567	 PR-R-V 0.907888749	
AMPK_pT172-R-V	 0.648308037	
GSK3-alpha-
beta_pS21_S9-R-V	 0.473012898	 PRAS40_pT246-R-V	 0.94253289	
Annexin_I-R-E	 0.816678879	 GSK3_pS9-R-V	 0.465773117	 PTEN-R-V	 0.012928935	
AR-R-V	 0.774308054	 HER2_pY1248-R-C	 0.779326792	 Rab11-R-E	 0.481445113	
Bad_pS112-R-V	 0.248710276	 HER3-R-V	 0.823319459	 Rab25-R-E	 0.427027919	
Bak-R-E	 0.233740918	 HER3_pY1298-R-C	 0.239195226	 Raptor-R-V	 0.010958233	
Bax-R-V	 0.606409335	 IGFBP2-R-V	 0.704959898	 Rb_pS807_S811-R-V	 0.431076702	
Bcl-xL-R-V	 0.133610074	 INPP4B-G-E	 0.277609698	 RBM15-R-V	 0.435704677	
Beclin-G-C	 0.782365968	 IRS1-R-V	 0.076829417	 Rictor-R-C	 0.01282843	
beta-Catenin-R-V	 0.337687651	 JNK_pT183_pT185-R-V	 0.40961812	 Rictor_pT1135-R-V	 0.013255368	
Bid-R-C	 0.380470389	 JNK2-R-C	 0.143253633	 S6_pS235_S236-R-V	 0.787819865	
Bim-R-V	 0.666638882	 Lck-R-V	 0.510284394	 S6_pS240_S244-R-V	 0.192541095	
c-Kit-R-V 0.09584474	 MAPK_pT202_Y204-R-V	 0.040347328	 Smad1-R-V	 0.879881187	
c-Met_pY1235-R-V 0.179031136	 MEK1-R-V	 0.532053466	 Smad3-R-V	 0.257115147	
c-Myc-R-C 0.174496331	 MEK1_pS217_S221-R-V	 0.58581745	 Src_pY416-R-C	 0.758488526	
C-Raf-R-V 0.093590223	 mTOR-R-V	 0.17024293	 Src_pY527-R-V	 0.160185242	
C-Raf_pS338-R-E 0.140086355	 mTOR_pS2448-R-C	 0.051128166	 STAT3_pY705-R-V	 0.689276344	
Caspase-
7_cleavedD198-R-C	 0.914898043	 MYH11-R-V	 0.008008481	 STAT5-alpha-R-V	 0.364329377	
Caveolin-1-R-V	 0.132411194	 N-Cadherin-R-V	 0.484162258	 Stathmin-R-V	 0.34541852	
CDK1-R-V	 0.411494628	 NDRG1_pT346-R-V	 0.737156673	 TAZ-R-V	 0.227110567	
Chk1-R-E	 0.613940163	 NF-kB-p65_pS536-R-C 0.681260761	 TIGAR-R-V	 0.849650952	
Chk1_pS345-R-E	 0.970126703	 NF2-R-C	 0.005680786	 TRFC-R-V	 0.868867142	
Chk2_pT68-R-E	 0.539749452	 Notch1-R-V	 0.907635137	 TSC1-R-C	 0.836626998	
cIAP-R-V	 0.291991243	 p27-R-V	 0.943744838	 TTF1-R-V	 0.090061686	
Claudin-7-R-V	 0.180306755	 p27_pT157-R-C	 0.84505331	 Tuberin-R-E	 0.405520087	
Collagen_VI-R-V	 0.271316434	 p27_pT198-R-V	 0.12289665	 VEGFR2-R-V	 0.93708572	
Cyclin_B1-R-V	 0.007704679	 p38_MAPK-R-E	 0.327692275	 XRCC1-R-E	 0.680321327	
Cyclin_D1-R-V	 0.555298373	 p38_pT180_Y182-R-V	 0.24863432	 YAP-R-E	 0.427038632	
DJ-1-R-E	 0.483884585	 p53-R-E	 0.424599929	 YAP_pS127-R-E	 0.868654221	
Dvl3-R-V	 0.456762712	 p70S6K-R-V	 0.600343069	 YB-1-R-V	 0.044310894	
E-Cadherin-R-V 0.11154638	 p70S6K_pT389-R-V	 0.935826407	 YB-1_pS102-R-V	 0.463380059	




















Figure 2.1 Kaplan-Meier percent survival curves for BRAF-induced tumors 
demonstrate that loss of Pten or expression of myrAKT1 significantly increases 
tumor incidence and reduces tumor latency. Dct::TVA;Braf CA;Cdkn2alox/lox mice 
(PtenWT) were injected at birth with either Cre (small dashed line n = 34) or myrAkt1 and 
Cre (wide dashed line n = 27) containing viruses as indicated. Dct::TVA;Braf 
CA;Cdkn2alox/lox;Ptenlox/lox mice (Ptenlox/lox) were injected with viruses encoding Cre (solid 
black line n = 24). TVA negative Braf CA;Cdkn2alox/lox and BrafCA;Cdkn2alox/lox;Ptenlox/lox 
mice injected with Cre containing viruses (narrow dashed line n =40) and PtenWT mice 
injected with myrAkt1 containing viruses (off-width dashed line n=21) yielded no tumors 
and are shown as negative controls. A significant difference was observed between the 
survival of PtenWT mice injected with Cre containing viruses and PtenWT mice injected 
with myrAkt1  and Cre containing viruses (P = 2.3 x 10-9). A significant difference was 
also observed between the survival of PtenWT mice injected with Cre and myrAkt1 
containing viruses and Ptenlox/lox mice injected with Cre containing viruses (P = 0.045). 
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Figure 2.2 Pten loss in melanomas from Dct::TVA;BrafCA/CA;Cdkn2alox/lox;Ptenlox/lox
mice injected with Cre containing viruses. A: Viral delivery and expression of Cre 
recombinase was confirmed by RT-PCR on mouse primary tumors. B: Deletion of Pten 








Figure 2.3 Expression of myrAKT1 in melanomas from 
Dct::TVA;BrafCA/CA;Cdkn2alox/lox mice injected with myrAkt1 and Cre containing 
viruses. Virally delivered myrAkt1 expression was detected by IHC using an antibody to 
the HA epitope tag on myrAKT1. Tumors are shown by mouse ID number. Scale bar 
represents 200 µm.  
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Figure 2.4 Kaplan-Meier percent survival curves for BRAF-induced tumors 
demonstrate loss of Pten cooperates with AKT1 activation to accelerate tumor 
formation. Comparison of the mice whose tumors were found to express myrAKT1 
(wide dashed line n = 18) and mice whose tumors lacked Pten revealed no significant 
difference (P = 0.994) (solid black line n = 24). However, the survival of Ptenlox/lox mice 
injected with myrAkt1 and Cre containing viruses (solid gray line n = 14) differed 
significantly from the survival of Ptenlox/lox mice injected with Cre containing viruses (P = 
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Figure 2.5 Expression of myrAKT1 in melanomas from 
Dct::TVA;BrafCA/CA;Cdkn2alox/lox; Ptenlox/lox mice injected with myrAkt1 and Cre 
containing viruses. Virally delivered myrAkt1 expression was detected by IHC using an 
antibody to the HA epitope tag on myrAKT1. Tumors are shown by mouse ID number. 











Figure 2.6 Pten loss in melanomas from Dct::TVA;BrafCA/CA;Cdkn2alox/lox;Ptenlox/lox
mice injected with Cre and myrAkt1 containing viruses. A: Viral delivery and 
expression of Cre recombinase was confirmed by RT-PCR on mouse primary tumors. B: 









Figure 2.7 Histological analysis of BRAFV600E and myrAKT1 induced tumors. A-D: 
Tumors were induced in Dct::TVA;Braf CA;Cdkn2alox/lox mice (PtenWT) by subcutaneous 
injection of newborn mice with viruses containing myrAkt1 and Cre. A: Representative 
tumor H&E; B: Ki67 IHC; C: P-ERK IHC; D: IHC for HMB-45, gp100 and MART-1 
(pan-MEL). Scale bars represent 200 µm. E-H: Metastases to the lung were observed in 
PtenWT mice injected with myrAkt1 and Cre containing viruses. E: Representative gross 
lung with multiple metastatic lesions; F: Low magnification H&E of a lung with multiple 
melanoma metastases; G: Higher magnification H&E of a lung metastasis; H: HA IHC 
confirmed expression of myrAKT1. Scale bar represents 6 mm. I, J: Brain metastases 
were observed in PtenWT mice injected with myrAkt1 and Cre containing viruses. I: H&E 
of representative melanoma brain metastasis; J: HA IHC confirmed expression of 
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Figure 2.8 Comparison of AKT activity in mutant BRAF melanomas. The left panel 
(A, C, E, G) shows a representative H&E of the primary tumor and the right panel (B, D, 
F, H) shows P-AKT (pS473) IHC staining of an adjacent section. All tumors lack Cdkn2a 
expression and express mutant BRAF. Pten status and myrAKT1 expression are indicated 
on the left. Pertinent tumor genotypes are as follows: (A, B) BRAFV600E;Cdkn2a-/- ; (C, 
D) BRAFV600E;Cdkn2a-/-;Pten-/- ; (E,F) BRAFV600E ;Cdkn2a-/-; myrAKT1  and (G,H)
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Figure 2.9 Protein expression in mutant BRAF melanomas. Expression of myrAKT1-
HA was assessed in nine different tumor samples from three different genotypes:  
Cdkn2a-/-;BRAFV600E; Pten-/- (311, 3145, 3147), Cdkn2a-/-;BRAFV600E;myrAKT1  (445, 
446, 450) and Cdkn2a-/-; BRAFV600E;Pten-/-;myrAKT1  (5413, 5417, 5461). The cells 
were lysed in SDS lysis buffer and separated on 4–20% gradient polyacrylamide gels. 
Virally delivered myrAkt1 expression was detected with an antibody to the HA epitope 
tag on myrAKT1. Activation of AKT was evaluated by blotting for phosphorylated AKT 
(p-AKT) and comparing the levels of total AKT expression. Mutant BRAF expression 
was confirmed and downstream activity was evaluated by blotting for phosphorylated 
ERK1/2 (p-ERK1/2) and comparing the levels of total ERK1/2 expression. GAPDH 
expression was used as a loading control. 
 Pten -/-   myrAKT1 Pten-/-;
myrAKT1 HA 311
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Figure 2.10 Levels of phosphorylated AKT are higher in tumors that have lost Pten. 
Scatter plot shows quantification of immunoblots. Data points equal individual tumors 
(n=3). Solid line within data points equals geometric mean. Error bars represent standard 
error of the mean. 
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Figure 2.11 RPPA analysis of protein from Pten-null and myrAKT1 melanomas. 
Protein was isolated from Cdkn2a-/-;BRAFV600E;Pten-/- (Pten-/-) and Cdkn2a-/-
;BRAFV600E;myrAKT1 (myrAKT1) tumors; expression was assessed by RPPA. Log2 
expression data was subjected to unsupervised clustering and the results are presented as 
a heat-map. Tumors were labeled Pten-/- (gray squares) or myrAKT1 (blue squares). The 
heat-map shown represents the proteins and phosphorylated proteins with a significant 
difference (p < 0.05 using unpaired t tests) between myrAKT1 and Pten-/- tumors. An 
asterisk (*) denotes a primary tumor from a mouse with brain metastasis.   





Figure 2.12 Protein and phospho-protein levels from RPPA. Scatter plots show raw 
expression data from Pten-/- and myrAKT1 tumors according to targets that were 
significantly different (p < 0.05 using unpaired t tests) between the two tumor groups. 
Solid line within data points equals geometric mean. Error bars represent standard error 
of the mean. 
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CHAPTER 3 
DIFFERENTIAL METASTATIC POTENTIAL OF AKT 
ISOFORMS IN MELANOMA 
3.1 Introduction 
 Brain metastases are a major concern for patients with malignant melanoma. 
Three out of four patients with stage IV disease will develop brain metastasis, making 
this one of the most common complications of metastatic melanoma (Chaichana and 
Chaichana, 2011). Consequently, an estimated half of all melanoma deaths are attributed 
to brain metastases (Davies et al., 2011). Therapeutic advances for brain metastasis have 
lagged behind the recent breakthroughs in treatment for extracranial metastatic melanoma 
(Flanigan et al., 2011; Girotti et al., 2014). Our limited understanding of the mechanisms 
driving melanoma to the brain make clinical management and prognosis of this 
complication extremely difficult. Further investigation into the molecular mechanisms of 
brain-specific tropism is warranted to counter the clinical demands of melanoma brain 
metastasis.   
 Clinical and experimental data strongly implicate aberrant AKT activation in 
promoting melanoma brain metastasis (Dai et al., 2005; Davies et al., 2009; Niessner et 
al., 2013; Chen et al., 2014). Two independent studies comparing patient-matched brain 
versus extracranial melanoma metastases found that increased AKT acitivty is a  hallmark 
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of brain metastasis (Niessner et al., 2013; Chen et al., 2014). Another clinical study found 
that absence of detectable PTEN, a negative regulator of AKT activation, correlated with 
shorter time to brain metastasis among stage IIB/C melanoma patients with BRAFV600 
mutations (Bucheit et al., 2014). Niessner et al. observed that melanoma cells grown in 
astrocyte-conditioned media have much stronger induction of AKT activity and markedly 
increased invasive potential compared with cells grown in fibroblast-conditioned media 
(Niessner et al., 2013). We recently reported that expression of activated AKT1 in a non-
metastatic mouse model of melanoma results in highly metastatic disease with nearly 
80% incidence of brain metastasis (Chapter 2). These lines of evidence strongly support a 
role for AKT signaling in the pathogenesis of melanoma brain metastasis. 
 In mammals, AKT activation can occur through one of three isoforms: AKT1, 
AKT2, and AKT3. The AKT isoforms share ~80% amino acid sequence identity; 
however, in vivo studies indicate that they possess both redundant and nonoverlapping 
functions (Gonzalez and McGraw, 2009). Various human cancers hyper-activate a 
specific AKT isoform during tumorigenesis. In melanoma, activating mutations are 
observed in AKT1 and AKT3 but are yet to be found in AKT2 (Davies et al., 2008; Shi et 
al., 2014). Activating mutations in AKT1 confer a survival advantage for melanoma cells 
in vitro and are observed in the setting of drug-resistant, metastatic disease (Shi et al., 
2014). AKT isoform specific knock-down in melanoma cell lines  revealed that AKT3 is 
the predominately active isoform (Stahl et al., 2004). Aberrant AKT3 activity tempers 
MAPK signaling in mutant BRAF melanocytes and melanoma cells thus promoting 
oncogenic transformation rather than cellular senescence (Cheung et al., 2008). 
Collectively, these studies suggest that in melanoma, specific AKT isoforms may drive 
aberrant AKT signaling and subsequent pathology. 
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 Previously we reported a highly penetrant, spontaneous model of melanoma brain 
metastasis driven by activated AKT1 in the context of mutant BRAF and Ink4a/Arf loss 
(Chapter 2). Interestingly, deletion of Pten alone did not result in brain metastases but 
combined with activated AKT1 expression cooperated to accelerate tumor formation and 
increase the incidence of brain metastasis. These findings led us to hypothesize that 
activation of specific AKT isoforms might be responsible for promoting brain metastasis 
in this context. In our current study, we tested this hypothesis by expressing both wild-
type and activated AKT1, AKT2, or AKT3 in our established in vivo model of melanoma 
(VanBrocklin et al., 2010). We observed that expression of activated AKT1 and AKT3 
promotes the development of brain metastases in 18% and 55% of tumor-bearing mice, 
respectively. In contrast, expression of activated AKT2 or any of the wild-type AKT 
isoforms failed to yield brain metastasis in this context. Our observation of brain 
metastases in nearly 20% of mice expressing activated human AKT1 is in agreement with 
our previous findings with mouse AKT1 in the same context (Chapter 2). Our results 
specifically highlight a role for aberrantly activated AKT3 in promoting melanoma brain 
metastasis. Furthermore, melanoma gene expression analysis from The Cancer Genome 
Atlas (TCGA) database provides corroborating evidence of increased AKT3 expression 
in melanomas that metastasize to the brain compared to non-metastatic melanomas (Zhu 
et al., 2014). Taken together, these data support a mechanism whereby aberrant AKT1 
and AKT3 activation promotes melanoma metastasis to the brain. The results from our 
study demonstrate that the AKT isoforms differ in their ability to promote melanoma 
metastasis and provide a rationale for the development of therapies that specifically target 
AKT3 or its effectors to effectively combat melanoma brain metastasis.     
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3.2 Materials and Methods 
3.2.1 Generation of DCT::TVA;BrafCA;Ink4a/Arflox/lox mice. The melanoma 
model used in this study is based on the RCASBP(A)/TVA retroviral vector system and 
features in vivo melanocyte-specific infection via targeted expression of TVA, the viral 
receptor for the RCASBP(A) virus (VanBrocklin et al., 2010; von Werder et al., 2012). 
TVA expression under the control of the Dopachrome tautomerase (DCT) promoter 
(DCT::TVA) allows RCASBP(A) virus to specifically target melanocytes and facilitates 
somatic transfer of genetic information (Dunn et al., 2000; Steel et al., 1992). Transgenic 
DCT::TVA mice were bred with Ink4a/Arf lox/lox mice (Aguirre et al., 2003a) and Cre-
activated Braf (BrafCA) mice (Dankort et al., 2007a) to yield 
DCT::TVA;BrafCA;Ink4a/Arflox/lox mice. In the absence of Cre recombinase, 
DCT::TVA;BrafCA;Ink4a/Arf lox/lox mice express wild-type BRAF, p16INK4A and p19ARF 
(Aguirre et al., 2003b; Dankort et al., 2007b). Cre activity results in ablation of a 
functional p16Ink4a and p19Arf coding locus and recombination of the Braf allele to express 
mutant BRAFV600E. PCR was conducted to confirm mouse genotyping for the Dct::TVA 
transgene, Cdkn2alox, and BrafCA and wild-type alleles as described (Dankort et al., 
2007b; VanBrocklin et al., 2010) 
3.2.2 Production of RCASBP(A) viruses.  DF-1 chicken fibroblasts are an ideal 
host for RCASBP(A) viruses because of their proliferative capacity, their ease of growth 
in culture, and their endogenous expression of TVA. RCASBP(A) viral vectors 
containing FLAG tagged human AKT1, AKT2, or AKT3 with or without a myristoylation 
(myr) sequence (designated myrAKT1, myrAKT2, and myrAKT3 or wtAKT1, wtAKT2, 
and wtAKT3) (a kind gift from Wei Zhang) were transfected into DF-1 cells grown at 
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39°C in DMEM-high glucose media (Invitrogen, Waltham, MA USA) supplemented 
with 10% FBS (Invitrogen, Waltham, MA USA) using a calcium phosphate based 
method. Following reverse transcription, the viral DNA integrates into the host cell 
genome and produces infectious virus in transfected DF-1 cells. The produced infectious 
virus spreads within the media and eventually inoculates all the DF-1 cells in the culture 
plate. Expression of virally delivered genes was confirmed by Western blot using the 
following antibodies at the dilutions indicated: Akt1 (C73H10) Rabbit mAb #2938 (Cell 
Signaling, Danvers, MA USA) at 1:1000, Akt2 (D6G4) Rabbit mAb #3063 (Cell 
Signaling) at 1:1000, Akt3 (62A8) Rabbit mAb #3788 (Cell Signaling) at 1:1000, 
Monoclonal anti-FLAG M2 mAb F3165 (Sigma-Aldrich, St. Louis, MO USA) at 1:1000, 
Anti-beta Tubulin (HRP) pAb Ab21058 (Abcam, Cambridge, MA USA) at 1:1000, Anti-
rabbit IgG, HRP-linked Ab #7074 (Cell Signaling) at 1:1000, and Anti-mouse IgG, HRP-
linked Ab #7076 (Cell Signaling) at 1:2000. 
3.2.3 Injection of DCT::TVA;BrafCA;Ink4a/Arflox/lox neonatal mice with 
RCASBP(A) AKT isoform and Cre viruses. Confluent 10 cm plates of infected DF-1 
cells were trypsinized, pelleted, and resuspended in 50 µL of Hank’s balanced salt 
solution (HBSS; Invitrogen, Waltham, MA USA). Newborn 
DCT::TVA;BrafCA;Ink4a/Arflox/lox mice were subcutaneously injected behind the ears with 
virus-producing DF-1 cells between postnatal day 1 and postnatal day 5. Mice were 
serially injected over two rounds with a total volume of 200 µL of the following 
suspended DF-1 cells:  100 µL of suspended RCASBP(A) Cre cells  and 100 µL of either 
suspended RCASBP(A) myrAKT1, RCASBP(A) myrAKT2, RCASBP(A) myrAKT3, 
RCASBP(A) wtAKT1, RCASBP(A) wtAKT2, or RCASBP(A) wtAKT3 cells. The health 
84	
status of the mice and tumor development were monitored daily. 
3.2.4 Validation of AKT isoform expression in primary mouse melanomas. 
Expression of AKT isoforms was confirmed via Western blot by probing for the FLAG 
epitope on the virally-delivered AKTs. Tumors were isolated from 
DCT::TVA;BrafCA;Ink4a/Arf lox/lox mice injected with RCASBP(A) viruses containing 
Cre and myrAKT1, myrAKT2, myrAKT3, wtAKT1, wtAKT2, or wtAKT3. Samples of 
collected tumors were prepared for Western blot as previously described (See Chapter 2). 
The antibodies used for Western blot were monoclonal anti-FLAG M2 mAb F3165 
(Sigma-Aldrich) at 1:1000 dilution, Anti-beta Tubulin (HRP) pAb Ab21058 (Abcam) at 
1:1000 dilution, and Anti-mouse IgG, HRP-linked Ab #7076 (Cell Signaling) at 1:2000 
dilution. 
3.2.5 Hematoxylin and eosin staining of mouse melanomas, coronal brain 
sections and lungs. Mouse tissues were fixed overnight in 10% neutral buffered 
formalin, dehydrated in 70% ethyl alcohol, and paraffin-embedded. Tissues were cut at 
4µm thickness and adhered to glass slides. Tissue sections were stained with hematoxylin 
and eosin (H&E) or left unstained for immunohistochemistry. 
3.2.6 Immunohistochemistry (IHC) of primary mouse melanomas and brain 
metastases. Tissue sections were deparaffinized and rehydrated prior to antigen retrieval 
by boiling in 10 mM sodium citrate buffer at pH 6.0 for 20 minutes using a Decloaking 
Chamber (Biocare Medical, Concord, CA USA). Pre-treament with 3% hydrogen 
peroxide was employed to quench endogenous peroxidase activity and blocking was done 
with 5% normal goat serum #5425 (Cell Signaling) in 1× TBS/0.1% Tween-20 (TBS-T). 
Sections were incubated at 4 oC overnight with Phospho-Akt (S473) (D9E) XP® Rabbit 
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mAb #4060 (Cell Signaling) diluted 1:50 or Monoclonal anti-FLAG M2 mAb F3165 
(Sigma-Aldrich) diluted at 1:200 in SignalStain® Antibody Diluent #8112 (Cell 
signaling). The antibody solution was removed and tissue sections were washed three 
times in 1× TBS-T. Sections were incubated for 1 hour at room temperature in 
SignalStain® Boost IHC Detection Reagent (HRP, Rabbit) #8114 (Cell Signaling), 
followed by staining with SignalStain® DAB Substrate Kit #8059 (Cell Signaling). All 
sections were counterstained with hematoxylin.  
3.2.7 TCGA data analysis. Level 3 TCGA Skin Cutaneous Melanoma (SKCM) 
data was retrieved and processed using TCGA-Assembler software in the R statistical 
computing environment (Zhu et al., 2014). At the time of analysis, TCGA data was 
available from 437 individuals with melanoma. The patients were divided into two 
categories: patients with new tumor events (NTE) and patients without NTEs. Samples 
with missing NTE status or no information regarding the NTE were excluded (n = 117). 
The patients with NTE were stratified according to the type of NTE – distant metastasis, 
regional lymph node metastasis, locoregional recurrence, and new primary.  Patients with 
distant metastasis as the NTE were further subdivided according to presence of brain 
metastases (hereafter referred to as “brain metastatic”) or extracranial metastases. 
Patients without NTE were subdivided by submitted clinical samples - primary 
melanoma or metastatic tissue. The patient groups were as follows: 43 NTE patients with 
distant metastasis to the brain, 108 NTE patients with distant extracranial metastases, 18 
NTE patients with lymph node metastases, 20 NTE patients with locoregional recurrence, 
6 NTE patients with new primary melanomas, 125 patients without NTE.  Of the 125 
patients without NTE, 67 patients (hereafter referred to as “non-metastatic”) submitted 
86	
primary melanoma tissue for analysis. 
Taking a candidate approach, we investigated changes in copy number and gene 
expression for AKT1, AKT2, AKT3, PTEN, PICK3CA, PHLPP1, and PH domain and 
leucine rich repeat protein phosphatase 2 (PHLPP2). Copy number data processed by 
the TCGA-Assembler program was initially expressed as an output value equaling the 
transformed base2log(copy number/2) centered on 0. The output values were re-
transformed and centered to a normal copy number of 2. Patient-matched normal whole 
blood copy number data was used to normalize changes in melanoma tissue sample copy 
number. Gene expression data processed by the TCGA-Assembler was reported as 
normalized count values. 
3.2.8 Statistical analysis. Censored survival data was analyzed using R software 
to calculate log-rank tests of the Kaplan-Meier estimate of survival. For all other 
statistical analyses performed in this study, two-tailed student t-tests were conducted 
assuming unequal variance.   
3.2.9 Study approval. All animal experimentation was performed in AAALAC 
approved facilities at the University of Utah. All animal protocols were reviewed and 
approved prior to experimentation by the Institutional Animal Care and Use Committee 
at the University of Utah. 
3.3 Results 
3.3.1 AKT3 gene expression is significantly increased in melanomas that 
metastasize to the brain. Previous studies have reported an association between AKT 
gene loci amplification and melanoma (Bastian et al., 1998; Turner et al., 2015). We used 
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TCGA data to determine whether genomic amplification of AKT isoforms correlated with 
metastatic outcomes in melanoma. Significant differences in copy number were not 
observed between melanomas based on metastatic phenotype; however, in line with 
previous reports, AKT3 gene amplification is a consistent feature of malignant melanoma 
with an average copy number of 2.37 (Figure 3.1 and Table 3.1). Interestingly, while 
PTEN exhibits decreased copy number with averages between 1.6-1.7 in melanomas, no 
significant copy number variations were found for AKT1 or AKT2 (Figure 3.1 and Table 
3.1). We next sought to determine whether AKT3 gene expression varies between non-
metastatic melanomas and brain metastatic melanomas. Expression of AKT3 is 
significantly higher (P = 0.00076) in brain metastatic melanomas compared to non-
metastatic melanomas (Figure 3.2 and Table 3.2). In contrast, AKT1 expression is 
significantly decreased in melanomas that metastasize to the brain compared to non-
metastatic melanomas (P = 0.009) while no differences in expression are observed with 
AKT2 (Figure 3.2 and Table 3.2). Expression of PTEN, PI3KCAI, and PHLPP2 is 
significantly increased in brain metastatic melanomas compared to non-metastatic 
melanomas (Table 3.2).       
3.3.2 Expression of activated AKT3 increases melanoma incidence, decreases 
latency, and promotes brain metastasis. Given the TCGA data indicating that AKT3 
gene expression is significantly increased in brain metastatic melanomas relative to non-
metastatic melanomas, we tested whether in vivo expression of activated AKT3 in non-
metastatic melanomas promotes tumor growth and metastasis. Newborn 
Dct::TVA;BrafCA;Cdkn2alox/lox (PtenWT) mice were co-injected with RCASBP(A) Cre 
viruses and RCASBP(A) viruses containing myrAKT3 (Figure 3.3A). Of the PtenWT mice 
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injected with RCASBP(A) myrAKT3 and Cre viruses, 85% (11/13) developed tumors at 
the site of injection (Figure 3.3B, Figure 3.4 and Table 3.3). The mean survival of tumor-
bearing mice was 53 ± 6.8 days (Table 3.3). Expression of AKT3 in mouse melanomas 
was confirmed by Western blot (Figure 3.3B) and activated AKT was confirmed by IHC 
staining for phosphorylated AKT (Ser473) (Figure 3.5). As a control, newborn PtenWT 
mice were injected subcutaneously with RCASBP(A) Cre viruses alone. This cohort 
developed tumors at the site of injection in 47% (16/34) of the mice; mean survival of 
tumor-bearing mice in this cohort was 88.9 ± 8.6 days (Figure 3.4 and Table 3.3). A 
significant difference was observed in melanoma incidence and tumor latency between 
mice expressing activated AKT3 and control counterparts (P = 6.02 x 10-5; Figure 3.4). 
Upon euthanasia, all mice were examined for metastasis. Interestingly, 55% (6/11) of the 
mice whose melanomas expressed myrAKT3  developed brain metastases while none of 
the PtenWT mice injected with viruses containing Cre developed metastases to the brain 
(Figure 3.6 and Table 3.3). 
3.3.3 Activated human AKT1 promotes brain metastases similar to activated 
mouse AKT1. Our previous work showed that PtenWT mice injected with RCASBP(A) 
viruses containing Cre and activated mouse AKT1 developed melanomas in 88% (24/27) 
of mice and brain metastases were observed in 17% (3/18) of the mice whose tumors 
expressed myrAKT1 (Chapter 2). In this study, we tested whether expression of activated 
human AKT1 in the same context would promote melanoma metastasis. Newborn PtenWT 
mice were injected with RCAS viruses containing myrAKT1 and Cre. Tumors formed at 
the injection site in 79% (15/19) of the mice (Table 3.3). The mean survival of tumor-
bearing mice in this cohort was 56 ± 5.7 days (Table 3.3). Expression of AKT1 was 
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confirmed by Western blot (Figure 3.3B) and activated AKT signaling in tumor tissue 
was demonstrated by immunohistochemical (IHC) staining for phospho-AKT Ser473 
(Figure 3.7). A highly significant difference in tumor latency and incidence was observed 
between PtenWT mice injected with myrAKT1 and Cre viruses and PtenWT mice injected 
with Cre virus alone (P = 8.89 x 10-5) (Figure 3.4). Similar to tumor-bearing PtenWT mice 
injected with mouse myrAkt1and Cre viruses, PtenWT mice expressing human myrAKT1 
developed brain metastases in 13% (2/15) of the mice (Table 3.3). 
3.3.4 Expression of activated AKT2 increases melanoma incidence and 
decreases latency but does not promote brain metastasis. Newborn PtenWT mice were 
injected with RCASBP(A) viruses encoding myrAKT2 and Cre and monitored for tumor 
development. All injected PtenWT mice developed tumors at the site of injection (18/18; 
Figure 3.4 and Table 3.3). The mean survival of the mice in this cohort was 40 ± 1.6 days 
(Table 3.3). A highly significant difference in survival was observed compared to the 
PtenWT cohort injected with RCASBP(A) Cre alone (P < 1.00 x 10-5) (Figure 3.4). 
Confirmation of AKT2 expression was made via Western blot (Figure 3.3B) and 
activated AKT signaling was confirmed by IHC for phospho-AKT Ser473 (Figure 3.8). 
No brain metastases were observed in any of the mice whose tumors expressed myrAKT2 
3.3.5 Wild-type AKT isoforms increase melanoma incidence but do not promote 
brain metastasis. Following our results with activated AKT isoforms, we tested whether 
expression of AKT isoforms lacking the myristoylation sequence tag would promote 
melanoma development and metastasis in our in vivo melanoma model. Newborn PtenWT 
mice co-injected with RCASBP(A) viruses encoding wtAKT1 and Cre had a tumor 
incidence of 89% (8/9; Figure 3.9 and Table 3.3). The mean survival of the tumor-
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bearing mice in this cohort was 74 ± 5.3 days (Table 3.3). PtenWT mice injected with 
RCASBP(A) viruses encoding wtAKT2 and Cre had a tumor incidence of 84% (17/20; 
Figure 3.9 and Table 3.3). The mean survival of the tumor-bearing mice in this cohort 
was 62.2 ± 4.0 days (Table 3.3). Injection of RCASBP(A) wtAKT3 and Cre viruses into 
newborn PtenWT mice resulted in tumor formation in 70% of the mice (7/10; Figure 3.9 
and Table 3.3). The mean survival of the tumor-bearing mice in this cohort was 69 ± 5.3 
days (Table 3.3). Although expression of the AKT isoforms in our melanoma model led 
to significant increases in melanoma incidence compared to control PtenWT mice injected 
with RCASBP(A) Cre alone as demonstrated by the Kaplan-Meier survival curves 
(Figure 3.9), no observable brain metastases were observed in any of the mice whose 
tumors expressed wild-type AKT.  
3.3.6 Expression of activated AKT2 promotes melanoma lung metastasis. We 
previously reported that PtenWT mice injected with viruses containing mouse myrAKT1 
and Cre develop highly metastatic melanomas with metastases to the lungs and brain 
(Chapter 2). Therefore, we examined all major organs of the tumor-bearing mice for 
melanoma metastases. Lung metastases were observed at a frequency of 18%, 29%, and 
20% for melanomas expressing myrAKT1, myrAKT2, and myrAKT3, respectively, 
while no lung metastases were observed in tumor-bearing PtenWT mice injected with 
RCASBP(A) Cre alone (Table 3.3). However, using a Fisher’s exact test, we determined 
that only melanomas expressing myrAKT2 had a significant incidence of lung metastases 
when compared to mice with tumors only injected with Cre viruses (P = 0.0445). 
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3.4 Discussion 
 In this study, we investigated the metastatic potential of melanomas expressing 
different isoforms of AKT and observed that activation of AKT1 and AKT3 specifically 
promote brain metastases. We previously observed that PTEN silencing in melanoma 
does not mirror AKT1 activation in terms of promoting lung and brain metastases. This 
led us to hypothesize that activation of specific AKT-isoforms account for differences in 
metastatic potential. We observed that activated AKT3 expression in a non-metastatic 
mouse model of melanoma leads to lung and brain metastasis with 55% penetrance. In 
line with our previous findings, expression of activated AKT1 in non-metastatic 
melanomas results in lung and brain metastases with at incidence of 18%. Interestingly, 
expression of AKT2 or any of the wild-type AKT isoforms with Cre in this melanoma 
model leads to primary tumor growth and lung metastases but no observable brain 
metastases. Taken together, these findings suggest that the mechanisms driving 
melanoma to the brain are mediated through specific AKT isoforms.  
We observed brain metastases in mice bearing tumors driven by activated AKT1 
and AKT3. Mechanisms implicating AKT isoform-specific preferences in melanoma 
development and progression have previously been reported (Cheung et al., 2008; Stahl 
et al., 2004). Cheung et al. found that AKT3 cooperates with BRAFV600E by inhibitory 
phosphorylation, which tempers MAPK signaling to a level that promotes melanocyte 
proliferation and transformation (Cheung et al., 2008). Robertson and coworkers found 
clinical support for increased AKT3 activity in human melanomas compared with normal 
melanocytes and linked expression of AKT3 in melanomas with decreased apoptosis 
(Stahl et al., 2004). We previously demonstrated that expression of activated mouse 
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AKT1 is sufficient to elicit lung and brain metastasis in an in vivo non-metastatic model 
of melanoma (Chapter 2). In this study we observed similar patterns of metastasis when 
activated human AKT1 was expressed in the same context. Furthermore, we describe a 
novel finding that expression of activated AKT3 results in even higher incidence (55%) 
of brain metastasis than AKT1 in our in vivo model. While AKT3 has recently been 
associated with the pathogenesis of primary brain malignancies (Turner et al., 2015), this 
is to our knowledge the first report of AKT3 promoting melanoma metastasis to the 
brain.     
  Several lines of evidence point towards a neuro-developmental function of 
AKT3. The expression of AKT3 is predominately expressed in the brain and Akt3-/- mice 
exhibit a 20-25% decrease in brain size compared to than their wild-type littermates 
(Easton et al., 2005; Tschopp et al., 2005). Activating AKT3 mutations are associated 
with brain over-growth syndromes (Lee et al., 2012; Poduri et al., 2012; Riviere et al., 
2012) and genetic duplications involving the AKT3 locus are known to occur in patients 
with macrocephaly (Chung et al., 2014; Riviere et al., 2012; Wang et al., 2013). In 
contrast, patients with AKT3 deletion or loss of the genomic region encoding AKT3 
(1q44) exhibit features such as microcephaly, seizure phenotype, and cognitive deficits 
(Ballif et al., 2012; Gai et al., 2015). Taken together, these studies suggest that AKT3 
plays a prominent role in brain development and growth. 
While we find that AKT1 and AKT3 activation promotes brain metastasis in 
melanoma, AKT2 activation does not promote this phenotype and instead is associated 
with lung metastases and rapid tumor growth. These phenomena may be related to the 
role of AKT2 in glucose metabolism. Akt2 knock-out mice are impaired in glucose 
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metabolism and exhibit features of type II diabetes (Cho et al., 2001; Garofalo et al., 
2003). Adipocytes derived from Akt2-/- fibroblasts display markedly reduced glucose 
uptake upon insulin stimulation compared to fibroblast from Akt2 wild-type littermates 
(Bae et al., 2003; Hill et al., 1999). Insulin sensitivity is fully restored in AKT2-deficient 
adipocytes upon re-expression of AKT2 but not with overexpression of AKT1 (Bae et al., 
2003). Mechanistically, AKT2 promotes translocation of Glucose transporter 4 (GLUT4) 
to the plasma membrane in an isoform-specific manner via regulation of several 
downstream effectors, the best characterized being the Rab GTPase activating protein 
(GAP), AS160, which negatively regulates GLUT4 exocytosis in adipocytes and muscle 
cells (Eguez et al., 2005; Gonzalez et al., 2009; Ishikura and Klip, 2008; Sano et al., 
2007). Clinical evidence supports laboratory findings of AKT2-mediated glucose 
regulation. Inactivating mutations in AKT2 have been linked with familial insulin 
resistance and diabetes mellitus (George et al., 2004). Alternatively, activating mutations 
in AKT2 are associated with severe hypoglycemia and accelerated growth (Hussain et al., 
2011). The function of AKT2 in glucose homeostasis could explain the rapid tumor 
growth phenotype we observe in melanomas ectopically expressing activated AKT2 
(Figures 3.4 and Figure 3.9). 
Opposing or nonoverlapping roles of the AKT isoforms are well documented in 
the pathogenic processes of cancer, including metastasis. AKT1 and AKT2 are known to 
play opposing roles in mouse embryo fibroblast cell migration and regulation of the 
cytoskeleton. Using in vitro migration assays, Zhou et al. reported that Akt2 knock-out 
cells migrate faster than wild-type cells while Akt1-null cells migrate slower than wild-
type cells via a mechanism that involves differential isoform signaling through RAC and 
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PAK1 (Zhou et al., 2006). Distinct functional roles for the AKT isoforms are observed in 
disseminated tumor cells (DTC) found in the bone marrow of non-small cell lung cancer 
patients (Grabinski et al., 2011). While depletion of AKT3 and AKT1 reduces 
proliferation and survival of DTC cell lines in association with decreased levels of Cyclin 
D1 and impaired Epidermal growth factor (EGF)-dependent stimulation, knockdown of 
AKT2 in DTC cell lines does not reduce proliferation or survival (Grabinski et al., 2011). 
Irie et al. uncovered AKT isoform-specific differences in the regulation of cell migration 
and epithelial-mesenchymal transition using a 3D in vitro culture system to model breast 
cancer initiation and progression (Irie et al., 2005). AKT2 depletion in insulin-like 
growth factor-1 receptor (IGF-1R) stimulated breast epithelial cells (MCF-10A) 
abrogated hyper-proliferative and anti-apoptotic phenotypes while AKT1 down-
regulation significantly enhances in vitro cell migration by a mechanism involving ERK 
activation (Irie et al., 2005). Using two different in vivo mouse models of breast cancer, 
Muller and coworkers demonstrated that AKT1 expression accelerates mammary tumor 
development but decreases the incidence of lung metastasis. On the other hand, AKT2 
expression did not significantly affect tumor latency but dramatically increased the 
incidence of lung metastasis (Dillon et al., 2009).  Similarly, we observed a significant 
incidence of lung metastases in mice with tumors expressing activated AKT2 but not 
with other isoforms. These examples of AKT isoform-specific mechanisms suggest that 
the functions of the different AKT isoforms are not uniform and vary greatly depending 
on the cellular context.  
In this study, we found that expression of activated (myristolated), but not wild-
type, AKT results in a metastatic melanoma phenotype. To become fully activated, AKT 
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is phosphorylated at two critical residues, Thr308 and Ser473, by PDK1 and mTORC2, 
respectively (Alessi et al., 1997; Sarbassov et al., 2005).  Activation of AKT is limited by 
its access to the plasma membrane where phosphorylation occurs (Andjelkovic et al., 
1997). Following phosphorylation, AKT becomes locked into a catalytically active 
conformation (Andjelkovic et al., 1997; Bellacosa et al., 1998; Yang et al., 2002) and 
disperses from the plasma membrane to a variety of cellular locations including the 
cytoplasm, nucleus, and mitochondria where it acts on downstream effectors (Toker, 
2012). Compared to wild-type AKT, myristoylated AKT proteins display both increased 
and unregulated kinase activity in vitro (Mende, 2001). Expression of myristoylated AKT 
in chicken embryo fibroblasts exhibited stronger induction of oncogenic transformation 
by colony forming assay and promoted tumor formation in vivo while wild-type AKT 
isoforms lacked this ability (Mende, 2001). Our data supports these findings and suggests 
that expression of AKT1 or AKT3 in the context of melanomas driven by mutant 
BRAFV600E and silencing of INK4A and ARF, is not sufficient to elicit brain metastasis 
but that these proteins must also be aberrantly activated. This hypothesis could provide an 
explanation for our previous finding that PTEN loss cooperates with activated AKT1 to 
promote melanoma brain metastasis (Chapter 2). PTEN is a well-known negative 
regulator of AKT signaling and its loss could accentuate the dysregulated activation of 
myrAKT1 or myrAKT3 and thus further promote brain metastasis  (Chalhoub and Baker, 
2009). Whether this cooperative effect is due to enhanced AKT signaling or via an AKT-
independent mechanism downstream of PTEN will need to be further studied by 
expressing other activated AKT isoforms in the context of PTEN silencing and assessing 
melanoma growth and metastasis.  
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We previously reported that PTEN silencing in melanomas driven by mutant 
BRAFV600E and loss of INK4A/ARF does not yield a significant metastatic phenotype 
like that observed in similar melanomas with expression of activated AKT1 (Chapter 2). 
A potential mechanism that could explain this phenomenon is that PTEN silencing 
preferentially activates a specific AKT isoform that does not promote melanoma 
metastasis. Indeed, one group reported preferential activation of AKT2 following PTEN 
inactivation in melanoma cells (Nogueira et al., 2010). Our current study demonstrates 
that while expression of activated AKT3 and to a lesser degree activated AKT1 in our 
melanoma model results in brain metastasis, the expression of activated AKT2 does not 
yield any brain metastases. It is tempting to speculate that our earlier observed lack of 
metastasis in PTEN silenced melanomas is due to predominant signaling through the 
AKT2 isoform. Our current study establishes that AKT signaling through specific AKT 
isoforms yields different metastatic potential for melanoma, yet it remains to be 
determined whether PTEN silencing preferentially allows activation of a specific AKT 
isoform during melanoma progression and metastasis. 
Our findings that expression of aberrantly activated AKT3 results in a significant 
incidence (55%; 6/11) of melanoma brain metastasis and that AKT3 gene expression is 
significantly higher in human melanomas that metastasize to the brain compared to non-
metastatic melanomas strongly implicate AKT3 signaling in promoting melanoma brain 
metastasis. Several previous studies have implicated AKT3 signaling in 
melanomagenesis, both clinically and experimentally (Cheung et al., 2008; Davies et al., 
2008; Stahl et al., 2004). Characterized mechanisms of activated AKT3 include inhibition 
of apoptosis, regulation of angiogenesis, and activation of the DNA repair pathway 
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(Phung et al., 2015; Shao and Aplin, 2010; Turner et al., 2015). Whether or not theses 
mechanisms of activated AKT3 are responsible for the increase in brain metastasis will 
be determined in future studies.    
In summary, we report that expression of activated AKT3 and AKT1 in a non-
metastatic melanoma mouse model results in high incidence of lung and brain metastases. 
Notably, we find that in contrast to activated AKT2 expressing melanomas which 
significantly metastasize to the lungs, activation of AKT3 promotes melanoma brain 
metastasis and its expression is significantly upregulated in brain metastatic human 
melanomas. Future studies will focus on determining key downstream effectors and 
mechanisms of AKT3 signaling that promotes melanoma dissemination to the brain.       
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Table 3.1 Average copy number (CN) of selected genes reveals AKT3 gene 
amplification in brain metastatic and non-metastatic melanomas. The average CN 
with standard deviations are listed for several genes associated with AKT signaling in 
non-metastatic melanomas and brain metastasic melanomas. In both melanoma groups, 
average CN increase and decrease was observed for AKT3 and PTEN, respectively. The P 
values from comparison statistics between the two groups are listed. Copy number data 
for melanomas were acquired from The Cancer Genome Atlas (TCGA) database.    
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Table 3.2 Significant increase in AKT3 gene expression in brain metastatic 
melanomas relative to non-metastatic melanomas. The normalized gene expression 
with standard deviations are listed for several genes associated with AKT signaling in 
non-metastatic melanomas (n=66) and brain metastatic melanomas (n=43). The P values 
from comparison statistics between the two groups are listed. Significant differences in 
expression are noted for several genes, including AKT3 (P = 0.00076). Normalized gene 
expression data for melanomas were acquired from The Cancer Genome Atlas (TCGA) 
database.    
*TCGA-GN-A269 has no gene expression data.
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Table 3.3 Summary of tumor formation. Tumor incidence, mean survival ± standard 
error of the mean (SEM) and percent of tumor-bearing mice with lung and brain 
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Figure 3.1 Increased average copy number (CN) for AKT3 in melanoma but no 
significant difference in average CN for AKT isoforms between non-metastatic and 
brain metastatic melanomas. Average CN for non-metastatic melanomas (No NTE; 
n=67) are compared side-by-side with average CN for brain metastatic melanomas (Brain 
met; n=43). Error bars represent the standard error of the mean (SEM). Copy number data 
for melanomas were acquired from The Cancer Genome Atlas (TCGA) database. 
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Figure 3.2 Significant increase in AKT3 gene expression between non-metastatic and 
brain metastatic melanomas. Normalized gene expression for non-metastatic 
melanomas (No NTE; n=66) are compared side-by-side with normalized gene expression 
for brain metastatic melanomas (Brain met; n=43). AKT3 gene expression is significantly 
higher (P = 0.0008) in brain metastatic melanomas compared to non-metastatic 
melanomas. \Brain metastatic melanomas have significantly decreased (P = 0.009) AKT1 
gene expression compared to non-metastatic melanomas. The difference in AKT2 gene 
expression between the two melanoma groups was not significant (N.S.). Error bars 
represent the standard error of the mean (SEM). Copy number data for melanomas were 
acquired from The Cancer Genome Atlas (TCGA) database. 
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Figure 3.3 Expression of activated AKT isoforms in DF-1 cells and melanomas. A: 
Expression of myrAKT1, myrAKT2 and myrAKT3 was assessed in respectively infected 
DF-1 cells using AKT isoform-specific and FLAG antibodies. B: Expression of 
myrAKT1, myrAKT2 and myrAKT3 was assessed in tumors induced by injection of 
RCASBP(A) Cre and respective myrAKT isoform viruses. Virally delivered myrAKT1, 
myrAKT2 and myrAKT3 expression was detected with an antibody to the FLAG epitope 
tag on the myrAKT isoforms. Tubulin expression was used as a loading control. Note: 
Sample 2374 was mistakenly classified as a myrAKT3 melanoma instead of a myrAKT2 
melanoma. 
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Figure 3.4 Kaplan-Meier percent survival curves demonstrate that expression of 
activated AKT isoforms significantly increases tumor incidence and reduces tumor 
latency. Dct::TVA;Braf CA;Cdkn2alox/lox mice (PtenWT) were injected at birth with either 
Cre (small dashed line n = 34), myrAKT1 and Cre (red line n = 19), myrAKT2 and Cre 
(green line n = 18), or myrAKT3 and Cre (blue line n = 13) containing viruses as 
indicated. Significant differences were observed between the survival of PtenWT mice 
injected with Cre containing viruses and the following: PtenWT mice injected with 
myrAKT1 and Cre containing viruses (P = 8.89 x 10-5), PtenWT mice injected with 
myrAKT2 and Cre containing viruses (P < 1 x 10-5), and PtenWT mice injected with 
myrAKT3 and Cre containing viruses (P = 6.02 x 10-5).  
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Figure 3.5 Robust activation of AKT in melanomas of 
Dct::TVA;BrafCA/CA;Cdkn2alox/lox mice (PtenWT) injected with myrAKT3 and Cre 
containing viruses. Representative P-AKT (pS473) IHC staining is shown from 
melanomas induced by injecting PtenWT with myrAKT3 and Cre containing viruses. 
Tumors are shown by mouse ID number. The letter B next to the mouse ID indicates the 
image is a brain metastasis. Tumor tissues were unavailable from the following 
experimental mice: 2141, 2348, and 2635. Scale bar represents 200 µm. 
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Figure 3.6 AKT activity in myrAKT3 driven melanoma brain metastases. The row of 
images representative H&E of the melanoma brain metastases. Mouse ID numbers are 
written above the images. The middle row of images show P-AKT (pS473) IHC staining 
of an adjacent section. The bottom row are adjacent sections probed for FLAG by IHC 
staining to confirm the presence of myrAKT3. Scale bar represents 200 µm.  
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Figure 3.7 AKT activity in melanomas of Dct::TVA;BrafCA/CA;Cdkn2alox/lox mice 
(PtenWT) injected with myrAKT1 and Cre containing viruses. Representative P-AKT 
(pS473) IHC staining is shown from melanomas induced by injecting PtenWT with 
myrAKT1 and Cre containing viruses. Tumors are shown by mouse ID number. Scale bar 
represents 200 µm. Note: Mouse 2492 developed a tumor after 100 days (experimental 
endpoint) and was thus considered negative when calculating tumor incidence. P-AKT 
IHC for tumor mouse 2942 is shown. 
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Figure 3.8 AKT activity in melanomas of Dct::TVA;BrafCA/CA;Cdkn2alox/lox mice 
(PtenWT) injected with myrAK2 and Cre containing viruses. Representative P-AKT 
(pS473) IHC staining is shown from melanomas induced by injecting PtenWT with 
myrAKT2 and Cre containing viruses. Tumors are shown by mouse ID number. Tumor 
tissues were unavailable from the following experimental mice: 2375, 2462, and 2471. 
Scale bar represents 200 µm.  
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Figure 3.9 Kaplan-Meier percent survival curves demonstrate that expression of 
wild-type AKT isoforms significantly increases tumor incidence. Dct::TVA;Braf 
CA;Cdkn2alox/lox mice (PtenWT) were injected at birth with either Cre (small dashed line n 
= 34), wtAKT1 and Cre (orange line n = 9), wtAKT2 and Cre (solid black line n = 20), or 
wtAKT3 and Cre (blue line n = 10) containing viruses as indicated. Significant 
differences were observed between the survival of PtenWT mice injected with Cre 
containing viruses and the following: PtenWT mice injected with wtAKT1 and Cre 
containing viruses (P = 0.00215), PtenWT mice injected with wtAKT2 and Cre containing 
viruses (P = 1.7 x 10-5), and PtenWT mice injected with wtAKT3 and Cre containing 
viruses (P = 0.0242).  
CHAPTER 4 
AKT3E17K PROMOTES MELANOMA LUNG METASTASES 
4.1 Introduction 
Melanoma is not only the most aggressive form of skin cancer, it also boasts one 
of the highest average mutation burdens amongst all cancer types (Alexandrov et al., 
2013). Large-scale sequencing studies reveal that genetic alterations in melanoma are not 
entirely random and instead implicate specific cellular pathways in the initiation and 
progression of this malignancy (Hodis et al., 2012; Krauthammer et al., 2012). Recent 
breakthroughs in melanoma therapy with targeted inhibitors have defined driver 
mutations in this disease (Chapman et al., 2011; Flaherty et al., 2012; Hodis et al., 2012). 
Thus, melanoma’s genomic mutational landscape shapes our current understanding of the 
disease and continues to hold mechanistic secrets. 
The AKT pathway is aberrantly activated in up to 70% of melanomas (Davies et 
al., 2009a; Smalley, 2009). Genomic alterations that contribute to increased AKT 
signaling in melanoma range from activating mutations and gene copy number 
amplification in AKT itself to gene deletions, inactivating mutations and DNA 
hypermethylation in other genes involved in the pathway. Melanomas acquire activating 
mutations in NRAS and PIK3CA, two positive AKT regulators, in 15-25% and 1-2% of  
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cases, respectively (Davies and Samuels, 2010). The negative AKT regulator, 
Phosphatase and tensin homolog (PTEN), is silenced by gene deletion, 
truncating mutations or inactivating mutations in 10-30% of melanomas. PHLPP1, a 
phosphatase that selectively deactivates AKT2 and AKT3, is suppressed at the  gene 
expression level in melanoma by a mechanism that involves DNA methylation and 
promoter-specific inhibition (Dong et al., 2014). Finally, isoforms of AKT are known to 
acquire activating mutations (1-2%) as well as increased copy number in melanoma 
(Bastian et al., 1998; Davies et al., 2008). These genomic changes contributing to AKT 
activation highlight the significance of activated AKT in melanoma.  
Aberrant AKT activation is strongly implicated in driving melanoma progression 
and brain-specific metastasis (Dai et al., 2005; Davies et al., 2009b).  The overexpression 
of AKT in a radially growing melanoma cell line confers an invasive, vertical 
growth phenotype when implanted in mice (Govindarajan et al., 2007). Clinical 
biopsies reveal that melanoma brain metastases have significantly higher levels of 
activated AKT compared with melanoma lung and liver metastases (Davies et al., 
2009b; Niessner et al., 2013). Follow-up studies comparing patient-matched brain 
versus extra-cranial melanoma metastases confirmed increased AKT activity as a 
specific feature of brain metastasis (Chen et al., 2014). We recently demonstrated 
that expression of activated AKT1 in a non-metastatic in vivo model of PTEN-null 
melanoma is sufficient to promote brain metastases at an incidence of 79% (Chapter 
2). Furthermore, activated AKT3 expression in a non-metastatic in vivo model of 
PTEN wild-type melanoma yields brain metastases in 55% of animals (Chapter 3). 
These data firmly establish the importance of activated AKT in melanoma metastasis; 
however, the question  remains as  to  what  is  “activated AKT”  and  what  level  of 
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activation is required?  
Phosphorylation of AKT at key residues is required for full activation of this 
kinase (Datta et al., 1999; Toker, 2012). These residues, known as threonine 308 
and serine 473, are phosphorylated by PDK-1 and mTORC2, respectively (Alessi et al., 
1997; Sarbassov et al., 2005). Phosphorylation at these two sites locks AKT into a 
catalytically active conformation and is rate limited by the recruitment of AKT to 
the cellular membrane (Andjelkovic et al., 1997; Bellacosa et al., 1998; Yang et al., 
2002). The affinity of the pleckstrin homology (PH) domain of AKT for 
phosphatidylinositol-3,4,5-triphosphate (PIP3) on the inner leaflet of the cellular 
membrane promotes AKT recruitment to the membrane and induces a conformational 
change in AKT that facilitates the activating phosphorylation events (Toker, 2012). PIP3 
levels are regulated by two key enzymes, Phosphatidylinositol-4,5-bisphosphate 3-
kinase (PI3K) and PTEN (Chalhoub and Baker, 2009). PI3K converts 
phosphatidylinositol-4,5-bisphosphate (PIP2)  to PIP3 while PTEN is a phosphatase that 
drives the reverse reaction and decreases the levels of PIP3. In this way, PI3K and 
PTEN act in an antagonistic fashion in terms of regulating AKT signaling. Once AKT 
is activated by phosphorylation, it disperses to a variety of cellular locations including 
the cytoplasm, nucleus, and mitochondria where it acts on downstream effectors 
(Toker, 2012).  
The PH domain of AKT is critical for AKT membrane recruitment and activation 
(Andjelkovic et al., 1997; Bellacosa et al., 1998). The binding of PIP3 to the PH domain 
of AKT is driven by ionic interactions between the negatively charged PIP3 phosphate 
groups and the positively charged residues found in the PH domain (Thomas et al., 2002). 
Deletion of the PH domain abolishes binding to PIP3, results in loss of membrane  
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targeting and reduced AKT activation (Andjelkovic et al., 1997; Thomas et al., 2002). 
Conversely, replacing the PH domain with a myristoylation sequence is sufficient to 
rescue AKT membrane recruitment and subsequent activation (Aoki et al., 1998; Kohn et 
al., 1996). Furthermore, certain mutations in the PH domain of AKT are associated with 
constitutive AKT activation (Carpten et al., 2007; Parikh et al., 2012; Shi et al., 2014).  
The most notable AKT PH domain mutation is a substitution of glutamate to 
lysine at the 17th amino acid residue (E17K), which changes the PH domain conformation, 
induces aberrant subcellular localization, and increases AKT activity in an oncogenic, 
transformative manner (Carpten et al., 2007). The E17K mutation is found in all three 
AKT isoforms and is associated with a variety of clinical pathologies, including 
melanoma (Davies et al., 2008; Hussain et al., 2011; Lindhurst et al., 2011; Shi et al., 
2014). Given the prominent role of AKT hyper-activation in melanomagenesis, it is not 
surprising that E17K mutations in AKT1 and AKT3 are found in 1-2% of melanomas 
(Davies et al., 2008). These AKT mutations are anecdotally associated with melanoma 
brain metastasis and drug-resistance mechanisms; however, in vivo functional studies 
have yet to be conducted (Davies et al., 2009a; Shi et al., 2014). 
Our previous work demonstrated that activated AKT3 is sufficient to promote 
metastases to the brain and lung in an established non-metastatic, mouse model of 
melanoma (Chapter 3). We expressed human myristoylation sequence tagged 
(myr)AKT3 in BrafV600E;Ink4a/Arf-null melanomas and observed brain metastasis in 55% 
(6/11) of the mice. In the current study, we set out to determine the role of AKT3E17K in 
melanoma formation and metastasis. Using our established non-metastatic mouse models 
of  melanoma  driven  by   BRAFV600E; INK4A/ARF  loss,   we   tested   tumor  incidence,
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growth, organ-specific metastasis, and overall survival of mice with melanomas 
expressing AKT3E17K. 
4.2 Materials and Methods 
4.2.1 Generation of DCT::TVA;BrafCA;Ink4a/Arflox/lox mice. Previously, we 
described a murine model of melanoma based on the RCAS/TVA retroviral vector 
system, which allows for tissue- and cell-specific infection of mammalian cells through 
ectopic expression of the viral receptor (VanBrocklin et al., 2010; von Werder et al., 
2012). This system utilizes a viral vector, RCASBP(A), derived from the avian 
leukosis virus (ALV). The receptor for RCASBP(A) is encoded by the TVA gene and is 
normally expressed in avian cells. Transgenic mice expressing TVA under the 
control of the Dopachrome tautomerase (DCT) promoter, which allow specific targeting 
of melanocytes (Dunn et al., 2000; Steel et al., 1992), were crossed with Ink4a/Arf lox/lox 
mice (Aguirre et al., 2003) and mice carrying a Cre-activated allele of Braf (BrafCA) 
(Dankort et al., 2007b) to generate DCT::TVA;BrafCA;Ink4a/Arf lox/lox mice. In the 
absence of Cre, the BRafCA allele expresses wild-type BRAF. Following Cre-
mediated recombination, BRAFV600E is expressed at physiological levels and 
undergoes normal differential exon usage and alternative splicing (Dankort et al., 
2007b). Exons 2 and 3 of the Ink4a/Arf locus are flanked by LoxP sites such that in 
the absence of Cre, these mice express normal levels of p16INK4A and p19ARF. 
Cre-mediated excision eliminates functional p16Ink4a and p19Arf (Aguirre et al., 2003). 
DNA from tail biopsies were genotyped by PCR for the Dct::TVA transgene, Cdkn2alox, 
and BrafCA and wild-type alleles as previously described (Dankort et al., 2007a; a  raf  an  wild-type alleles as previously described (Dankort et al., 2007a; 
VanBrocklin et al., 2010). 
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4.2.2 Construction of RCASBP(A) viral vector containing AKT3E17K. The 
retroviral vectors in this study are replication-competent ALV, Bryan polymerase-
containing vectors of envelope subgroup A [designated RCASBP(A)]. The RCASBP(A) 
vector is Gateway compatible allowing for efficient transfer of DNA into the retroviral 
vector (Loftus et al., 2001). To construct RCASBP(A) HA-AKT3E17K, we employed PCR-
based site-directed mutagenesis to create a transition at the 49th base of AKT3 cDNA (a 
gift from Wei Zhang) from guanine to alanine. A hemagglutinin (HA) epitope encoding 
sequence was placed at the N-terminus of AKT3. The HA-AKT3E17K cDNA was cloned 
into a pCR8 entry vector and verified for correct sequence and orientation. The attL sites 
flanking the 5ʹ and 3ʹ ends of the HA-AKT3E17K cDNA in the pCR8 vector allowed 
efficient transfer of the transgene into the RCASBP(A) vector containing attR sites upon 
incubation with a cocktail of bacteriophage lambda and E. coli enzymes (LR Clonase II; 
Invitrogen, Waltham, MA USA) yielding RCASBP(A) HA-AKT3E17K. 
4.2.3 Production of infectious RCASBP(A) HA-AKT3E17K virus. DF-1 chicken 
fibroblasts were grown at 39°C in DMEM-high glucose media (Invitrogen) supplemented 
with 10% FBS. Viral infection of RCASBP(A) HA-AKT3E17K  was initiated by calcium 
phosphate transfection of plasmid DNA into DF-1 cells. Viral spread was monitored by 
GFP positive control transfection and viral expression of AKT3E17K was validated by 
Western blot. Viral infectivity was confirmed by inoculating TVA-expressing C3 murine 
melanocytes with filtered (0.45 µm filter) supernatant from RCASBP(A) HA-AKT3E17K  
infected DF-1 cells in the presence of 8 µg/mL polybrene. 
4.2.4 Injection of DCT::TVA;BrafCA;Ink4a/Arflox/lox neonatal mice with 
RCASBP(A) AKT3E17K and Cre viruses. Infected DF-1 cells were trypsinized, pelleted, 
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and resuspended in 50 µL Hank’s balanced salt solution (HBSS; Invitrogen). The viral-
producing cells were subcutaneously injected behind the ears of newborn mice between 
postnatal day 1 and postnatal day 5. Mice received a total of 100 µL of suspended 
RCASBP(A) AKT3E17K cells and 100 µL of suspended RCASBP(A) Cre cells over two 
rounds of injection. Mice were then monitored daily for tumor development. 
4.2.5 RT-PCR validation of AKT3E17K expression in primary mouse tumors. To 
assess gene expression of AKT3E17K in primary mouse tumors, total RNA was extracted 
from mouse primary tumors using TRIzol reagent (Invitrogen, Waltham, MA USA) and 
chloroform. Precipitated nucleic acid was column purified using RNEasy Mini Kit 
(Qiagen, Hilden, Germany). SuperScript III First-Strand Synthesis System (Invitrogen, 
Waltham, MA USA) was employed to synthesize cDNA from total RNA. PCR reactions 
were set up using EconoTaq Plus Green 2x Master Mix (Lucigen, Middleton, WI USA). 
The forward PCR primer was as follows: 5ʹ-GGTGGAGGACCAGATGATGCAAAAG-
3ʹ and designed to anneal within the AKT3E17K cDNA. The reverse PCR primer was as 
follows: 5ʹ-GAAAGCTGGGTCTAGATTATTCTCGTCCAC-3ʹ and specifically 
complemented the 3ʹ end of the AKT3E17K transgene and the attB2 site from the 
RCASBP(A) vector. The expected PCR amplicon from this reaction was 289bp.  
4.2.6 Hematoxylin and eosin staining of mouse melanomas, coronal brain 
sections, and lungs. Mouse tissues were fixed in 10% neutral buffered formalin 
overnight, cut into three sections, and then dehydrated in 70% ethyl alcohol. Tissues were 
paraffin-embedded, sectioned at a thickness of 4µm, and placed on glass slides. Sections 
were stained with Hematoxylin and Eosin (H&E) or left unstained for 
immunohistochemistry. 
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4.2.7 Expression of AKT3E17K by Immunohistochemistry (IHC) staining for HA 
in primary mouse tumors. Tissue sections were hydrated and deparaffinized. Antigen 
retrieval was performed by boiling sections in 1× Rodent Decloaker buffer (Biocare 
Medical, Concord, CA USA) for 20 minutes in a Decloaking Chamber (Biocare 
Medical). Endogenous peroxidase activity was quenched by incubating sections in 3% 
hydrogen peroxide for 10 minutes. Sections were then blocked in Rodent Block (Biocare 
Medical) for 30 minutes. The HA-tagged, exogenous AKT3E17K was detected using a 
primary antibody to the HA epitope (HA.11, Covance, Princeton, NJ USA), diluted 
1:1000 in Renaissance Background Reducing Diluent (Biocare Medical). Sections were 
incubated overnight at 4°C and probed with Mouse on Mouse HRP polymer reagent 
(Biocare Medical). Visualization was carried out with DAB (Biocare Medical). All 
sections were counterstained with hematoxylin. 
4.2.8 Statistical analysis. Censored survival data was analyzed using R software 
to calculate a log-rank test of the Kaplan-Meier estimate of survival.  
4.2.9 Study approval. All animal experimentation was performed in AAALAC 
approved facilities at the University of Utah. All animal protocols were reviewed and 
approved prior to experimentation by the Institutional Animal Care and Use Committee 
at the University of Utah. 
4.3 Results 
4.3.1 Expression of AKT3E17K promotes BRAFV600E/INK4A-ARFNull melanoma 
growth. We previously observed metastatic melanomas in 85% (11/13) of 
DCT::TVA;BrafCA;Ink4a/Arf lox/lox (PtenWT) mice co-injected with RCASBP(A) Cre and 
125 
myrAKT3 viruses (Chapter 3; Figure 4.1).  In addition to primary tumors at the site of 
injection, these mice also developed brain and lung metastases in 55% and 20% of the 
tumor-bearing mice, respectively (Chapter 3).  We chose to extend our study of aberrant 
AKT3 signaling in melanomagenesis by testing whether expression of mutant AKT3E17K 
enhances BRAFV600E/INK4A-ARFNull melanoma initiation, growth, or metastasis 
similarly to our observations with myrAKT3 expression. Neonatal PtenWT mice were co-
injected with infectious RCASBP(A) Cre and RCASBP(A) AKT3E17K viruses (Figure 
4.2A, B). Tumors developed at the injection site in 69% (9/13) of injected PtenWT mice. It 
is important to note that AKT3E17K expression is not required for tumor formation in the 
context of BRAFV600E/INK4A-ARF silencing as tumors develop in nearly half of 
Dct::TVA; Braf CA; Cdkn2alox/lox mice infected with viruses encoding Cre alone (Chapter 
2; Figure 4.1). Of the nine tumor-bearing mice, eight had tumors with confirmed 
expression of AKT3E17K (Figure 4.3A, B). The mean survival for the confirmed 
AKT3E17K cohort was 73.6 ± 7.2 days (Table 4.1). Compared to PtenWT mice injected 
with Cre virus alone, the AKT3E17K melanoma mice had significantly increased tumor 
incidence and decreased survival (P=0.007; Figure 4.1). Statistically significant 
differences in survival were not observed between AKT3E17K melanoma mice and 
myrAKT3 or wtAKT3 melanoma mice (Figure 4.1). 
4.3.2 Expression of AKT3E17K in BRAFV600E/INK4A-ARFNull melanomas yields 
highly metastatic lung disease. Upon euthanasia all major organs of the tumor-bearing 
mice were examined for melanoma metastases. Interestingly, metastatic melanoma cells 
were detected in the lungs of 100% (8/8) of the mice harboring melanomas with 
confirmed expression of AKT3E17K (Figure 4.4). In contrast, no lung lesions were 
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observed in the one Cre and AKT3E17K injected tumor-bearing PtenWT mouse without 
confirmed expression of AKT3E17K (5168; not shown). 
4.3.3 Brain metastases are not observed in PtenWT mice with 
BRAFV600E/INK4A-ARFNull melanoma expressing AKT3E17K. In contrast to 
BRAFV600E/INK4A-ARFNull melanomas expressing myrAKT3 that spontaneously 
metastasize to the brain in 55% of tumor-bearing mice, no brain metastases were 
observed in PtenWT mice with BRAFV600E/INK4A-ARFNull melanoma expressing 
AKT3E17K (0/8; Figure 4.5). 
4.4 Discussion 
The present study was conducted to determine the role of AKT3E17K in melanoma 
growth and metastasis. The AKT signaling pathway plays a key role in cellular processes 
such as cell growth, metabolism, proliferation, and survival (Bellacosa et al., 2003; 
Gonzalez and McGraw, 2009; Xu et al., 2012). Melanoma is known to aberrantly activate 
this pathway to promote disease progression (Davies et al., 2009a; Smalley, 2009). E17K 
mutations in AKT1 and AKT3 occur in 1-2% of melanomas and represent one mechanism 
by which AKT activation occurs in this disease (Davies et al., 2008). We found that in 
vivo expression of AKT3E17K in BRAFV600E/INK4A-ARFNull melanomas results in 
aggressive lung metastases in 100% of tumor-bearing mice. We initially hypothesized 
that AKT3E17K would act similarly to myrAKT3 in BRAFV600E/INK4A-ARFNull 
melanomas; however, unlike the myrAKT3 mice that frequently succumb to brain 
metastasis, no cranial lesions were observed in any of the tumor-bearing AKT3E17K mice 
(0/8). This study, while still in progress, contributes to our current understanding of 
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mutant AKT3E17K in melanomagenesis and promises to reveal more about the role of 
aberrant AKT signaling in melanoma metastasis. 
Substitution of lysine in place of glutamate at the 17th amino acid position (E17K) 
creates a bona fide AKT activating mutation. In addition to melanomas, AKT1E17K 
mutations are associated with ovarian, breast, colorectal, and lung cancers (Carpten et al., 
2007; Malanga et al., 2008). Proteus syndrome is characterized by epithelial tissue over-
growth of skin, connective tissue, brain, and other tissues (Lindhurst et al., 2011). 
Somatic mosaicism for AKT1E17K mutation was detected in 26 out of 29 Proteus 
syndrome patients, suggesting this mutation and AKT activation plays a prominent role 
in driving the overgrowth phenotype. AKT2E17K mutation has been reported in association 
with severe hypoglycemia and an asymmetrical left-sided overgrowth (Hussain et al., 
2011). The hypoglycemia phenotype is consistent with AKT2 activation, given AKT2’s 
established role in glucose metabolism (Cho et al., 2001; Garofalo et al., 2003). To date, 
melanoma is the only malignancy associated with AKT3E17K mutations (Davies et al., 
2008). In vitro studies demonstrate that the E17K mutation promotes AKT recruitment to 
the cell membrane where it is activated (Carpten et al., 2007). AKT1E17K mutant protein 
shows much greater localization to the membrane over the wild-type protein. In addition, 
the E17K mutation also confers gain of function to AKT1. While AKT1E17K is sufficient 
to rescue glucose metabolism in AKT2-null cells, wild-type AKT1 and AKT3 are 
incapable of this function (Gonzalez et al., 2009). Furthermore, AKT1E17K expression in 
hematopoietic stem cells induces oncogenic transformation and leukemia when 
transduced into mice (Carpten et al., 2007).   
Two mechanisms might explain how E17K mutations promote activation of AKT. 
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The 17th amino acid is located within PH domain of AKT, a domain that physically 
interacts via intermolecular forces with PIP3 on the cell membrane. One mechanism 
suggests that lysine substitution at the 17th position increases the electrostatic attraction 
between the PH domain and PIP3, thus facilitating AKT membrane localization and 
subsequent activation. Indeed, x-ray crystallography of mutant AKT1E17K confirms 
enhanced  binding of the PH domain with PIP3 and in vitro cell culture assays with E17K 
mutations in all three AKT isoforms demonstrate increased membrane localization and 
activation (Carpten et al., 2007; Davies et al., 2008; Hussain et al., 2011). An alternative 
mechanism suggests that the E17K mutation facilitates the opening up or unmasking of 
the catalytic domain of AKT. Prior to AKT activation, the PH domain interacts with the 
kinase domain of AKT and the 17th amino acid is located at the contacting interface of 
the two domains (Parikh et al., 2012). Mutations perturbing the PH domain–kinase 
domain interaction lead to increased AKT activation as measured by phosphorylation of 
threonine 308 and serine 473. In their landmark study, Carpten et al. interestingly noted 
that the activity of AKT1E17K was unaffected by treatment with an AKT inhibitor that 
blocks membrane association and with  PI3K inhibition, implying a mechanism of 
activation independent of PH domain-PIP3 interaction (Carpten et al., 2007). This 
phenomenon could be explained by the alternative mechanism where E17K mutations 
disrupt PH domain-kinase domain interactions and thereby enhance AKT activation. 
Given the evidence supporting both mechanisms and the nonmutual exclusivity of the 
two mechanisms, it is likely that both PH domain-PIP3 interactions are enhanced and PH 
domain-kinase domain interactions are disrupted in E17K mutations of AKT. 
The in vivo functional consequence of AKT E17K mutant proteins in melanoma 
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development and progression is not well understood. We embarked on a study to test the 
role of AKT3E17K in a BRAFV600E/INK4A-ARFNull mouse model of melanoma. 
Previously, we showed that AKT activation, specifically AKT1 and AKT3, promotes 
melanoma metastasis to the brain (Chapter 2, 3). Based on our previous results, we 
hypothesized that AKT3E17K expressing BRAFV600E/INK4A-ARFNull melanomas would 
metastasize to the brain; however, this outcome was not observed and instead we 
observed highly aggressive lung tumors. The lung tumors appear to be metastatic lesions 
from the primary melanomas, but additional confirmatory evidence is required.  
Clinically, AKT1E17K mutations are also observed in melanomas. We are currently 
generating RCASBP(A) Akt1E17K virus for injection along with RCASBP(A) Cre into 
DCT::TVA;BrafCA;Ink4a/Arflox/lox to test the role of AKT1E17K in the context of 
BRAFV600E/INK4A-ARFNull melanoma development and metastasis. We also observed in 
previous studies that Pten silencing cooperates with AKT activation in promoting 
melanoma brain metastasis (Chapter 2). We are currently testing the role of AKT3E17K in 
BRAFV600E/INK4A-ARFNull/PTENNull melanoma development and metastasis. Future 
experiments will also test AKT1E17K in this context. 
The research presented in this chapter is a work in progress and should be 
considered in that context. Many control and follow-up experiments are required before 
any conclusions are drawn. A critical experiment yet to be conducted is determining 
whether the E17K mutation in AKT3 results in increased in vivo AKT activation in our 
melanoma model. Also of interest is a comparison of the differences in molecular targets 
between myrAKT3 and AKTE17K expressing BRAFV600E/INK4A-ARFNull melanomas to 
determine why one leads to brain metastasis in 55% of mice while the other yields no 
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observable brain metastases. The highly aggressive lung lesions are of interest and will be 
followed-up, especially given that the lungs are one of the most frequent sites of 
melanoma metastasis (de la Monte et al., 1983). Overall, the research described in this 
chapter increases our understanding of mutant AKT3E17K in BRAFV600E/INK4A-ARFNull 
melanomas and reveals an unexpected aggressive phenotype which we will continue to 
investigate with on-going research.  
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Dct::TVA;Braf CA;Cdkn2alox/lox Cre 16/34 88.9	± 8.6






Dct::TVA;Braf CA;Cdkn2alox/lox myrAKT3; Cre 11/13 53.5	± 6.8
Dct::TVA;Braf CA;Cdkn2alox/lox wtAKT3; Cre 7/10 68.6	± 5.3
*HA positive by IHC and/or positive by RT-PCR
Table 4.1 Summary of tumor formation. The mean survival (days) and tumor incidence
(fraction of tumor-bearing mice per cohort) are listed for each mouse cohort according to
genetic background and virally delivered genes.
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Pten wt: Cre (n=34)
Pten wt: Cre + wtAKT3 (n=10)
Pten wt: Cre + AKT3E17K (n= 13)





Figure 4.1 Kaplan-Meier percent survival curves demonstrate that expression of 
AKT3E17K significantly increases tumor incidence and reduces tumor latency. 
Dct::TVA;Braf CA;Cdkn2alox/lox mice (PtenWT) were injected at birth with either Cre (small 
dashed line n = 34), AKT3E17K and Cre (black line n = 13), myrAKT3 and Cre (green line n 
= 13), or wtAKT3 and Cre (blue line n = 10) containing viruses as indicated. A significant 
difference was observed between the survival of PtenWT mice injected with Cre containing 

























Figure 4.2 Expression of AKT3E17K in DF-1 cells and primary melanocytes. A:
Expression ofAKT3E17K was detected in infected DF-1 with an antibody to the HA epitope
tag on AKT3E17K. DF-1 cells expressing HA tagged mouse AKT1 was used as a positive
control. B: C3 primary melanocytes that ectopically express the TVA receptor were
inoculated with RCASBP(A) AKT3E17K virus produced from infected DF-1 cells. Virally
delivered AKT3E17K expression was detected with an antibody to the HA epitope tag on



































Figure 4.3 Expression of AKT3E17K in BRAFV600E/INK4A-ARF-null mouse
melanomas. A: Expression of AKT3E17K was assessed by RT-PCR using primers specific
for the transgene product. B: Expression of AKT3E17K was assessed in tumors induced by
injection of RCASBP(A) Cre and AKT3E17K viruses by IHC using an antibody to the HA
epitope tag on AKT3E17K. Scale bar represents 200 µm. Note: Tumor fromMouse ID 5198















































Figure 4.4 Histological examination reveals aggressive lung lesions in PtenWT mice
injected with RCASBP(A) Cre and AKT3E17K viruses. Lung lesions were observed in
100% (8/8) of tumor-bearing mice with confirmed expression of AKT3E17K. Shown above





Figure 4.5 Absence of observable brain metastasis in PtenWT mice injected with
RCASBP(A) Cre and AKT3E17K viruses. Brain sections from tumor-bearing mice with
confirmed expression of AKT3E17K were negative for observable metastasis. H&E stained
sections are shown bymouse ID number.
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CHAPTER 5 
SUMMARY AND PERSPECTIVES 
5.1 Introduction 
The work presented in this dissertation examines the role of AKT signaling in 
melanoma metastasis. Although previous clinical studies and in vitro work have 
implicated aberrant AKT activation as a mechanism driving melanoma metastasis, 
studies addressing the in vivo role of activated AKT in melanoma progression and 
metastasis were lacking (Dai et al., 2005; Davies et al., 2009; Stahl et al., 2004). Loss of 
PTEN is often considered a surrogate marker of AKT activation and in combination with 
mutant BRAF results in melanomas that metastasize to the lungs and lymph nodes in less 
than 10% of mice (Dankort et al., 2009). Interestingly, our data demonstrates that 
aberrant AKT activation differs from Pten loss in terms of promoting melanoma 
metastasis and that AKT signaling in melanoma metastasis is mediated via activation of 
specific AKT isoforms. This chapter summarizes the work presented in prior chapters 
and concludes with perspectives for future work. 
5.2 Chapter Summaries 
Chapter 2 of this dissertation describes our finding that expression of activated 
AKT1 in the context of mutant BRAFV600E and Cdkn2a loss results in highly aggressive 
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melanomas that metastasize to the brain and lungs. We report that while PTEN silencing 
does not result in significant metastasis in this context, loss of PTEN cooperates with 
activated AKT1 in promoting brain metastasis at an incidence of nearly 80% in tumor-
bearing mice. In this chapter, we show that targets of the mTOR pathway are upregulated 
and implicated in eliciting melanoma lung and brain metastasis. To our knowledge, the 
mouse model of metastatic melanoma described in this chapter is the first in vivo 
autochthonous model of melanoma lung and brain metastasis in an immunocompetent 
animal. This model system provides a powerful platform to further study the mechanisms 
of melanoma metastasis and sheds light on the involvement of AKT signaling in this 
process.    
Chapter 3 builds on our findings in Chapter 2 and investigates the role of AKT 
isoform-specific signaling in melanoma progression and metastasis. Our previous finding 
that PTEN silencing and expression of activated AKT1 does not yield similar metastatic 
phenotypes led us to hypothesize that AKT isoform-specific signaling facilitates the 
metastatic potential of melanoma cells. Using our non-metastatic in vivo model of 
melanoma, we identified AKT3 as the dominant isoform promoting AKT-mediated 
metastasis to the brain. We also found that in human melanomas that metastasize to the 
brain, AKT3 gene expression is significantly increased compare to non-metastatic 
melanomas. Expression of activated AKT1 elicits the formation of melanoma brain 
metastases at a lower incidence compared with activated AKT3 in PtenWT mice; however, 
expression of activated AKT2 in this context does not result in brain metastases. 
Furthermore, we found that the expression of wild-type AKT isoforms in PtenWT mice 
also does not promote brain metastases. Taken together, these findings indicate that 
aberrant activation of AKT3 and to a lesser extent AKT1 but not AKT2 is critical in 
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promoting melanoma metastasis to the brain in the context of BRAFV600E and 
INK4A/ARF loss.  
 Chapter 4 describes our studies investigating the role of AKT3E17K in melanoma 
development and progression. The E17K mutation has been found in all three isoforms 
and is thought to result in aberrant AKT signaling. The E17K mutations of AKT1 and 
AKT3 have been described in metastatic melanoma and are found in 1-2% of melanomas. 
Using our previously described non-metastatic mouse model of melanoma, we expressed 
AKT3E17K in the context of BRAFV600E and INK4A/ARF loss. Interestingly, brain 
metastases were not observed in our study however very aggressive lung lesions were 
noted. While it remains too early to draw conclusions, our work suggests that AKT3E17K 
is not functionally equivalent to activated (myristoylated) AKT3 in promoting melanoma 
metastasis and instead possess alternative neomorphic functions.  
 
5.3 Perspectives for Future Work 
 The current understanding of metastasis holds that in order for melanoma to 
colonize the brain, several steps must occur. These steps include local infiltration of 
tumor cells into adjacent tissue of the primary melanoma, intravasation of melanoma 
cells into a blood vessel, survival in the circulatory system, arrest at a branch point in the 
cerebral vasculature, extravasation through the blood-brain barrier, persistent close 
contact to microvessels, and perivascular growth by vessel co-option (Kienast et al., 
2010; Zbytek et al., 2008). How melanoma cells acquire the ability to fulfill these steps of 
metastasis is an active area of research. The previous chapters of this dissertation describe 
experiments that clearly demonstrate the critical role of aberrant AKT signaling in the 
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development of melanoma brain metastasis. Both experimental and clinical data strongly 
implicate aberrantly activated AKT3 in promoting melanoma spread to the brain. Moving 
forward, we aim to elucidate the specific step(s) of melanoma brain metastasis that 
aberrant AKT3 signaling facilitates.       
 Theories regarding melanoma’s tropism for the brain can be categorized 
mechanistically as either intrinsic or extrinsic. An example of a theory based on an 
intrinsic mechanism would be linking melanoma’s predilection for the brain with the 
neural crest origin of melanoma cells. A theory based on extrinsic mechanisms would 
consider factors of the brain that are specifically favorable for melanoma colonization 
such as being an immune-privileged site. While it is very plausible that both intrinsic and 
extrinsic views are valid and play a role in melanoma’s spread to the brain, the work 
presented in this dissertation favors the theory of an intrinsic mechanism. Using a non-
metastatic mouse model of melanoma, we observed that expression of either activated 
AKT3 or AKT1 in melanoma cells is sufficient to elicit lung and brain metastasis in the 
context of BRAFV600E and INK4A/ARF loss. Furthermore, our findings – that aberrant 
AKT3 and/or AKT1 activity in melanoma cells promotes metastasis to the brain – are 
supported by human data, which indicates that AKT signaling is a signature feature of 
brain metastases (Chen et al., 2014; Improta et al., 2011; Niessner et al., 2013).            
 The regulation of angiogenesis during early colonization of the brain parenchyma 
is a distinguishing feature between melanoma cells and other cancer cells that metastasize 
to the brain. In vivo studies by Kienast et al. showed that melanoma cells differs from 
lung cancer cells during the establishment of brain metastases by promoting perivascular 
growth by vessel co-option rather than early angiogenesis (Kienast et al., 2010). 
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Interestingly, a different study on vascular tumor growth found that aberrant AKT3 
activation inhibits angiogenesis by a mechanism involving mTOR signaling. Given our 
findings that expression of activated AKT3 is sufficient to elicit brain metastasis, it is 
tempting to speculate that activated AKT3 in melanoma cells might oppose early 
angiogenesis and thereby facilitate the perivascular growth and vessel co-option of brain 
micro-metastases. Whether this is the case will need to be determined in future studies.   
The predominant expression of AKT3 in the brain along with changes in brain 
growth depending on its presence, absence or function, demonstrate that AKT3 plays a 
critical role in brain development (Easton et al., 2005; Gai et al., 2015; Lee et al., 2012; 
Tschopp et al., 2005). It is known that melanoma cells colonizing the brain adopt neuron-
like characteristics, especially during the early metastatic growth phase in the brain 
(Nygaard et al., 2014). The mechanisms driving plasticity of melanoma cells during brain 
colonization are not well understood. The exact role of AKT3 signaling during brain 
development is also unknown. It is reasonable to hypothesize that AKT3 activation 
promotes a brain-adaptive phenotype in melanoma cells and thus confers an advantage 
for growing in the brain. As of yet, brain-specific molecular targets of AKT3 have not 
been identified in melanoma. 
Aberrant AKT signaling is associated with increased brain-specific invasiveness 
of melanoma cells (Niessner et al., 2013). Using a trans-well invasion assay with 
astrocyte-conditioned media as an attractant, Niessner et al. found that both AKT 
activation and an invasive phenotype increased in melanoma cells relative to control 
conditions using fibroblast conditioned media as an attractant. These findings are in line 
with general increased invasiveness in melanoma conferred by AKT overexpression 
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(Govindarajan et al., 2007). Whether aberrant AKT3 or AKT1 activation promotes brain-
specific invasion of melanoma cells crossing the blood-brain barrier or whether increased 
invasiveness is a general phenomenon from AKT signaling remains to be determined.        
Genomic amplification of AKT3 in glioma was recently linked to tumor 
progression via activation of the DNA repair pathway (Turner et al., 2015). DNA repair 
proteins are frequently overexpressed in breast cancer cells that metastasize to the brain 
(Woditschka et al., 2014). While ectopic expression of DNA repair proteins BARD1 or 
RAD51 in MDA-MB-231-BR cells increased brain metastasis formation by 3 to 4-fold in 
mice, siRNA mediated knockdown of RAD51 decreased brain metastasis formation 
nearly 3-fold (Woditschka et al., 2014). In our study, we found that in addition to AKT3 
copy number amplification, AKT3 gene expression is significantly upregulated in brain 
metastatic melanomas relative to non-metastatic melanomas. Whether aberrant AKT3 
activation induces DNA repair machinery in melanomas will be determined by future 
studies. 
The implications of this dissertation extend into the clinical management of 
melanoma. There is an acute need for more sophisticated tools to prognosticate a 
melanoma patient’s risk for metastasis. Our findings that aberrant AKT1/3 activation in 
the context of BRAFV600E and INK4A/ARF null melanomas leads to significant lung and 
brain metastases while myrAKT2 and AKT3E17K expression in the same context results in 
lung but not brain metastases indicates that aberrant AKT signaling drives melanoma 
metastasis via isoform or mutant-specific mechanisms. The TCGA database reveals that 
melanomas metastasizing to the brain have significantly higher expression of AKT3 
compared to non-metastatic melanomas. Collectively, these data suggest that aberrant 
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AKT isoform/mutant signaling not only plays a role in driving melanoma metastasis but 
that increased expression of specific AKT isoforms or mutants may predict the risk of 
melanoma metastasis to specific organs such as the brain.    
 The therapeutic implications of our study argue that targeting the 
PI3K/AKT/mTOR pathway may impede melanoma metastasis. Our findings are 
corroborated by other in vivo studies also implicating the role of unregulated mTOR 
signaling in melanoma progression and metastasis (Damsky et al., 2015; Liu et al., 2012). 
Several melanoma preclinical studies have demonstrated that PI3K/AKT inhibition 
retards cell growth, promotes tumor regression and delays the emergence of drug 
resistance to MAPK inhibitors (Bedogni et al., 2006; Lassen et al., 2014; Marsh Durban 
et al., 2013). Preliminary data from our lab reveals that dual inhibition of PI3K and 
mTOR using NVP-BEZ235 robustly inhibits in vitro migration of BRAF mutant 
melanoma cells (unpublished) and implies that increased migration downstream of 
aberrant AKT activation may contribute to the metastatic phenotypes observed in our in 
vivo studies. Currently, several clinical trials are underway testing the efficacy of 
PI3K/AKT/mTOR inhibitors in combination with other therapies for the treatment of 
metastatic melanoma (Fedorenko et al., 2015). However, early inhibition of the 
PI3K/AKT/mTOR pathway in melanoma at Stage 3 (regional lymph node involvement) 
or lower, where there is a dearth of therapeutic options, may prove more efficacious than 
after melanoma has disseminated to distant organs. Our study and in vivo model provides 
the optimal platform to test whether early intervention with PI3K/AKT/mTOR blockade 
is an effective strategy against the metastatic spread of melanoma.  
 As a part of on-going research, we plan to continue investigating aberrant AKT 
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isoform specific signaling and E17K mutant AKT proteins in melanoma development 
and progression. We are specifically interested in continuing the work pertaining to 
melanoma brain metastasis and aberrant AKT activation. The work presented in this 
dissertation establishes the role of aberrantly activated AKT1 and AKT3 in eliciting 
melanoma brain metastasis in a non-metastatic mouse model of melanoma featuring 
mutant BRAFV600E and Cdkn2a loss. We demonstrate that PTEN silencing is not 
equivalent to AKT1 activation in terms of metastatic potential in melanoma and that 
expression of activated AKT1 in melanoma results in significantly increased mTOR 
signaling compared to melanomas with Pten loss. We considered AKT isoform-specific 
signaling in melanoma and found that AKT3, and to a lesser extent AKT1, promotes 
melanoma brain metastasis while AKT2 activation does not. We are currently exploring 
the role of AKT3E17K in melanoma and have noted phenotypic differences from 
melanomas expressing activated AKT3. 
 Brain metastases are a major cause of death in melanoma (Budman et al., 1978; 
Davies et al., 2011; Yashin et al., 2013). The AKT pathway is aberrantly activated in up 
to 70% of melanomas and is clinically correlated with melanoma brain metastasis (Chen 
et al., 2014; Davies et al., 2009; Niessner et al., 2013; Smalley, 2009). Our work provides 
the first in vivo evidence that aberrant AKT3 and AKT1 activity are sufficient to elicit 
brain metastases in melanomas harboring BRAFV600E mutation and loss of Cdkn2a locus. 
Furthermore, our work demonstrates that PTEN silencing is not equivalent to AKT1 
activation in terms of promoting melanoma metastasis. We also developed the first 
autochthonous in vivo model of melanoma brain metastasis. Our work continues with 
investigating AKT isoform specific signaling and melanoma metastasis as well as the 
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E17K mutation of AKT in melanoma. Finally, work presented in this dissertation 
provides insights into the mechanism of melanoma brain metastasis that may prove useful 
in the future management of this disease complication.       
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